Biology, Clinical Patterns, and Treatment of Multiple Myeloma and Related Plasma–Cell Dyscrasias

  • Mehdi Farhangi
  • Elliott F. Osserman
Part of the Comprehensive Immunology book series (COMIMUN, volume 4)


The common denominator in ail plasma–cell dyscrasias (PCDs) is the inordinate expansion of differentiated B–cell clones (plasma cells) capable of synthesis and secretion of immunoglobulin (Ig) or its subunits. The structurally homogeneous secreted proteins can be demonstrated in the serum and urine of the overwhelming majority of patients. In only rare instances can no secreted product be demonstrated, and infrequently, two or more clones can be shown to occur simultaneously (see Section 4.1.10f).


Multiple Myeloma Monoclonal Protein Cold Agglutinin Bence Jones Protein Myeloma Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abbruzzo, J. L., Heimer, R., Guiliano, V., and Marting, J., 1970, The hyperviscosity syndrome, polysynovitis, polymyositis and an unusual 13 S serum IgG component. Am. J. Med. 49: 258.Google Scholar
  2. Abdou, N. I., and Abdou, N. L., 1975, The monoclonal nature of lymphocytes in multiple myeloma, Ann. Intern. Med. 83: 42–45.PubMedGoogle Scholar
  3. Abraham, D., Carbone, P. P., Venditti, J. M., Kline, I., and Goldin, A., 1967, Evaluation of chemical agents against the plasma cell tumor LPC-1 in mice, Biochem. Pharmacol. 16: 665.PubMedGoogle Scholar
  4. Abramson, N., and Shattil, S. J., 1973, M-components, J. Am. Med. Assoc. 223: 156.Google Scholar
  5. Adams, W. S., Alling, E. L., and Lawrence, J. S., 1949, Multiple myeloma: Its clinical and laboratory diagnosis with emphasis on electrophoretic abnormalities. Am. J. Med. 6: 141.PubMedGoogle Scholar
  6. Afifi, A. M., and Tawfeek, S., 1971, Deafness due to Waldenstrom’s macroglobulinemia, J. Laryngol Otol 85: 275.PubMedGoogle Scholar
  7. Alberts, D. S., and Golde, D. W., 1974, DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy. Cancer Res. 34: 2911–2914.PubMedGoogle Scholar
  8. Alberts, D. S., Durie, B. G., and Salmon, S. E., 1976, Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse. Lancet 1: 926–928.PubMedGoogle Scholar
  9. Alexanian, R., 1975, Monoclonal gammopathy in lymphoma, Arch. Intern. Med. 135: 62–66.PubMedGoogle Scholar
  10. Alexanian, R., Bergsagel, D. E., Migliore, P. J., Vaughn, W. K., and Howe, C. D., 1968, Melphalan therapy for plasma cell myeloma, Blood 31: 1.PubMedGoogle Scholar
  11. Alexanian, R., Haut, A., Khan, A. U., Lane, M., McKelvey, E. M., Migliore, P. J., Stuckey, W. J., Jr., and Wilson, H. E., 1969, Treatment for multiple myeloma, J. Am. Med. Assoc. 208: 1680.Google Scholar
  12. Alexanian, R., Bonnet, J., Gehan, E., Haut, A., Hewlett, J., Lane, M., Monto, R., and Wilson, H., 1972, Combination chemotherapy for multiple myeloma, Cancer 30: 382–389.PubMedGoogle Scholar
  13. Alexanian, R., Balcerzak, S., Bonnet, J. D., Gehan, E. A., Haut, A., Hewlett, J. S., and Monto, R. W., 1975a, Prognostic factor in multiple myeloma. Cancer 36: 1192–1201.PubMedGoogle Scholar
  14. Alexanian, R., Balcerzak, S., Haut, A., Hewitt, J., and Gehan, E. (for the Southwest Oncology Group), 1975b, Remission maintenance therapy for multiple myeloma. Arch. Intern. Med. 135: 147.Google Scholar
  15. Andersen, B. R., 1966, Gamma A-cold agglutinin: Importance of disulfide bonds in activity and structure, Science 154: 281–283.PubMedGoogle Scholar
  16. Anderson, E. T., and Vye, M. V., 1967, Dysproteinemia of the myeloma type associated with a thymoma, Ann. Intern. Med. 66: 141.PubMedGoogle Scholar
  17. Anderson, S., Yeung, K., Hillman, D., and Lessin, L., 1975, Multiple myeloma in a patient with sickle cell anemia: Interesting effects on blood viscosity, Am. J. Med. 59: 568–574.PubMedGoogle Scholar
  18. Angevine, C. D., Andersen, B. R., and Barnett, E. V., 1966, A cold agglutinin of IgA class, J. Immunol. 96: 578.PubMedGoogle Scholar
  19. Aoki, T., and Takahashi, T., 1972, Viral and cellular surface antigens of murine leukemias and myelomas, J. Exp. Med. 135: 433.Google Scholar
  20. Apitz, K., 1940, Die Paraproteinosen (über die Störung des Eiweisstoffwechsels bei Plasmacytom), Virchows Arch. Pathol. Anat. 306: 631.Google Scholar
  21. Arend, W. P., and Adamson, J. W., 1974, Nonsecretory myeloma: Immunofluorescent demonstration of paraprotein within bone marrow plasma cells, Cancer 33: 721–728.PubMedGoogle Scholar
  22. Axelsson, U., and Hallen, J., 1965, Familial occurrence of pathological serum-proteins of differenty-globulin groups. Lancet 2: 369.PubMedGoogle Scholar
  23. Axelsson, U., and Hällen, J., 1968, Review of 54 subjects with monoclonal gammopathy, Br. J. Haematol. 15: 417–420.PubMedGoogle Scholar
  24. Axelsson, U., Bachmann, R., and Hällen, J., 1966, Frequency of pathological proteins (M components) in 6,995 sera from an adult population. Acta Med. Scand. 179: 235–247.PubMedGoogle Scholar
  25. Azam, L., and Delamore, I. W., 1974, Combination therapy for myelomatosis, Br. Med. J. 4: 560–564.PubMedGoogle Scholar
  26. Azar, H. A., 1973, Pathology of multiple myeloma and related growths, in: Multiple Myeloma and Related Disorders, Vol. I ( H. A. Azar and M. Potter, eds.), pp. 1–85, Harper and Row, New York.Google Scholar
  27. Azar, H. A., and Potter, M. (eds.), 1973, Multiple Myeloma and Related Disorders, Vol. I, Harper and Row, New York.Google Scholar
  28. Azar, H. A., Hill, W. T., and Osserman, E. F., 1957, Malignant lymphoma and lymphocytic leukemia associated with myeloma type serum proteins, Am. J. Med. 23: 239–249.PubMedGoogle Scholar
  29. Bachmann, R., 1965, Simultaneous occurrence of two immunologically different M components in serum, Acta Med. Scand. 177: 593.PubMedGoogle Scholar
  30. Bain, B. J., Ribush, N. T., McPath, P. N., Whitesed, H. M., and Morgan, T. D., 1973, Renal failure and transient paraproteinemia due to Leptospira pomoma, Arch. Intern. Med. 131: 740–745.Google Scholar
  31. Baitz, T., and Kyle, R. A., 1964, Solitary myeloma in chronic osteomyelitis, Arch. Intern. Med. 113: 872–876.PubMedGoogle Scholar
  32. Balazs, V., and Fröhlich, M. M., 1966, Anti-complementary effect of cryoglobulinemic sera and isolated cryoglobulins. Am. J. Med. Sci. 251: 51–56.PubMedGoogle Scholar
  33. Ballard, H. S., Hamilton, L. M., Marcus, A. J., and Illes, C. H., 1970, A new variant of heavy-chain disease (chain disease), N. Engl. J. Med. 282: 1060–1062.PubMedGoogle Scholar
  34. Balthazar, E. J., and Cano, R., 1975, The radiology comer: Gastric myeloma, Am. J. Gastroenterol. 63 (4): 340–344.PubMedGoogle Scholar
  35. Bartels, E. D., Brun, G. C., Gammeltoft, A., and Gjømp, P. A., 1954, Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med. Scand. 150: 297–302.PubMedGoogle Scholar
  36. Barth, W. F., Glenner, G. G., Waldmann, T. A., and Zelis, R. F., 1968, Primary amyloidosis, Ann. Intern. Med. 69: 787–805.PubMedGoogle Scholar
  37. Bayrd, E. D., 1961, Continuous chlorambucil therapy in primary macroglobulinemia of Waldenstrom: Report of four cases, Proc. Staff Meet. Mayo Clin. 36: 135–147.PubMedGoogle Scholar
  38. Beaumont, J. L., 1967, Une spécificité commune aux α-et β-lipoproteines du serum revelée par un autoanticorps de myelome, C. R. Acad. Sei. Ser. D 264: 183–188.Google Scholar
  39. Beaumont, J. L., 1969, Gamma-globulines et hyperlipidémie par auto-anticorps, Ann. Biol. Clin. (Paris) 27: 611–635.Google Scholar
  40. Beaumont, J. L.. and Lorenzelli, L., 1967, L’auto-anticorps antilipoproteins (anti-Pg) du γ-A-myelome avec hyperlipidemie: Methode d’isolement et de purification a partir des complexes circulant, Ann. Biol. Clin. (Paris) 25: 655–675.Google Scholar
  41. Bedine, M. S., Yardley, J. H., Elliott, H. L, Banwell, J. G., and Hendrix, T. R., 1973, Intestinal involvement in Waldenstrom’s macroglobulinemia, Gastroenterology 65: 308–315.PubMedGoogle Scholar
  42. Beker, S. G., Grases, P. J., Merino, F., Arends, T., and Guevara, J., 1971, Intestinal malabsorption in macroglobulinemia. Am. J. Dig. Dis. New Ser. 16: 648–656.Google Scholar
  43. Benditt, E. P., and Eriksen, N., 1966, Amyloid. III. A protein related to the subunit structure of human amyloid fibrils, Proc. Natl. Acad. Sci. U.S.A. 55: 308.PubMedGoogle Scholar
  44. Benditt, E. P., Eriksen, N., Hermodson, M. A., and Ericsson, L. H., 1971, The major proteins of human and monkey amyloid substance: Common properties including unusual N-terminal amino acid sequences, FEBS Lett. 19: 169.PubMedGoogle Scholar
  45. Benhold, H., 1922, Fine spezifische Amyloid färbung mit Kongorot, Muench. Med. Wochenschr. 2: 1537.Google Scholar
  46. Benninger, G. W., and Kreps, S. I., 1971, Aggregation phenomenon in an IgG multiple myeloma resulting in the hyperviscosity syndrome, Am. J. Med. 51: 287.PubMedGoogle Scholar
  47. Bergsagel, D. E., 1976, The treatment of plasma cell myeloma, Br. J. Haematol. 33 (4): 443–449.PubMedGoogle Scholar
  48. Bergsagel, D. E., Sprague, C. C., Austin, C., and Griffith, K. M., 1962, Evaluation of new chemothera– peutic agents in the treatment of multiple myeloma. IV. 1-Phenylalanine mustard (NSC–8806), Cancer Chemother. Rep. 21: 87–99.PubMedGoogle Scholar
  49. Bergsagel, D. E., Griffith, K. M., Haut, A., and Stuckey, W. J., Jr., 1967, The treatment of multiple myeloma. Adv. Cancer Res. 10: 311.PubMedGoogle Scholar
  50. Bergsagel, D. E., Cowan, D. H., and Hasselback, R., 1972, Plasma cell myeloma: Response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Can. Med. Assoc. J. 107: 851–855.PubMedGoogle Scholar
  51. Berlin, S.-O, Odeberg, H., and Weingart, L., 1968, Familial occurrence of M-components, Acta Med. Scand. 183: 347.PubMedGoogle Scholar
  52. Bernhardt, B., Valbetta, M., Brook, J., and Lejnieks, I., 1972, Case report, amyloidosis with factor X deficiency, Am. J. Med. Sci. 264: 411–414.PubMedGoogle Scholar
  53. Bernier, G. M., and Graham, R. C., Jr., 1976, Plasma cell asynchrony in myeloma: Correlation of light and electron microscopy, Semin. Hematol. 13: 239–245.PubMedGoogle Scholar
  54. Bethlenfalvay, N. C., Henley, L. E., Rupp, T. D., and Phyliky, R. L., 1976, Nonsecretory plasma cell dyscrasia followed by acute granulocytic leukemia 25 years after thorotrast administration. Cancer 37 (3): 1449–1453.PubMedGoogle Scholar
  55. Bielschowsky, M., Helyer, B. J., and Howie, J. B., 1959, Spontaneous haemolytic anaemia in mice of the NZB/Bl strain, Proc. Univ. Otago Med. Sch. 37: 9.Google Scholar
  56. Bjerrum, O. J., and Weeks, B., 1968, Two M-components, γGK, γML, in different cells in the same patients, Scand. J. Haematol. 5: 215.PubMedGoogle Scholar
  57. Bloch, K. J.. and Maki, D. G., 1973, Hyperviscosity syndromes associated with immunoglobulin abnormalities, Semin. Hematol. 10: 113–124.PubMedGoogle Scholar
  58. Blokhin, N., Larionov, L., Perevodchikova, N., Chebotareva, L., and Merkulova, N., 1958, Clinical experiences with sarcolysin in neoplastic diseases, Ann. N.Y. Acad. Sci. 68: 1128–1132.PubMedGoogle Scholar
  59. Sohnstedt, R. M., and Ehlers, G., 1967, Mucinosis Papulosa (Myxomatosis cutis Papulosa, Liehen Myxoedem Bouroncle, B. A., Datta, P., and Frajola, W. J., 1964, Waldenstrom’s macroglobulinemia: Report of three patients treated with cyclophosphamide, J. Am. Med. Assoc. 189: 729–732.Google Scholar
  60. Bourreille, J., Hemet, J., Tayot, J., and Maitre, A.-M., 1974, Gastric localization of multiple myeloma, Sem. Hop. 50 (25): 1737–1742.PubMedGoogle Scholar
  61. Bouvet, J. P., Feingold, J., Oriol, R., and Liacopoulos, P., 1975, Statistical study on double paraproteinemias: Evidence for a common cellular origin of both myeloma globulins, Biomedicine 22: 517–523.PubMedGoogle Scholar
  62. Braun, D. G., and Krause, R. M., 1968, The individual antigenic specificity of antibodies to streptococcal carbohydrates, J. Exp. Med. 128: 969.PubMedGoogle Scholar
  63. Braun, D. G., Eichmann, K., and Krause, R. M., 1969, Rabbit antibodies to streptococcal carbohydrates, J. Exp. Med. 129: 809.PubMedGoogle Scholar
  64. Braun, D. G., Kindred, B., and Jacobson, E. B., 1972, Streptococcal group A carbohydrate antibodies in mice: Evidence for strain differences in magnitude and restriction of the response and for thymus dependence, Eur. J. Immunol. 2: 138.PubMedGoogle Scholar
  65. Brecher, G., Tanaka, Y., Malmgren, R. A., and Fahey, J. L., 1964, Morphology and protein synthesis in multiple myeloma and macroglobulinemia, Ann. N.Y. Acad. Sci. 113: 642–653.PubMedGoogle Scholar
  66. Bridgen, W. D., 1974, Papular mucinosis (scleromyxoedema of Arndt-Gottron) associated with paraprotein IgG kappa type, Proc. R. Soc. Med. 67: 200.Google Scholar
  67. Broder, S., Humphrey, R., Durm, M., Blackman, M., Meade, B., Goldman, C., Strober, W., and Waldmann, T., 1975, Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: Role of suppressor cells, N. Engl. J. Med. 293: 887–892.PubMedGoogle Scholar
  68. Brooks, A. P., 1976, Portal hypertension in Waldenstrom’s macroglobulinemia, Br. Med. J. 1(6011):689– 690.Google Scholar
  69. Brown, M., and Battle, J. D., Jr., 1964, The effect of urography on renal function in patients with multiple myeloma. Can. Med. Assoc. J. 91: 786–790.PubMedGoogle Scholar
  70. Brown, R. K., Read, J. T., Wiseman, B. K., and France, W. G., 1948, The electrophoretic analysis of serum proteins of the blood dyscrasias, J. Lab. Clin. Med. 33: 1523.PubMedGoogle Scholar
  71. Bush, S. T., Swedlund, H. A., and Gleich, G. J., 1969, Low molecular weight IgM in human sera, J. Lab. Clin. Med. 73: 194–201.PubMedGoogle Scholar
  72. Butler, W. T., and Rossen, R. D., 1973, Effect of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone, J. Clin. Invest. 52: 2629–2640.PubMedGoogle Scholar
  73. Callis, M. N., and Sheets, R. F., 1974, Multiple myeloma in Iowa, J. Iowa Med. Soc. 64: 429–433.Google Scholar
  74. Campbell, A. E., DeVine, J., Azam, L., Hamid, J., Delamore, I. W., and McFarlane, H., 1975, Lymphocyte transformation in patients with paraproteinaemia, Br. J. Haematol. 29: 179–188.PubMedGoogle Scholar
  75. Capra, J. D., and Hopper, J. E., 1976, Comparative studies on monotypic IgM λ and IgG κ from an individual patient. III. The complete aminoacid sequence of the VH region of the IgM paraprotein, Immunochemistry 13: 995–999.PubMedGoogle Scholar
  76. Capra, J. D., and Kunkel, H. G., 1970, Aggregation of 7G3 proteins: Relevance to the hyperviscosity syndrome, J. Clin. Invest. 49: 610.PubMedGoogle Scholar
  77. Capra, J. D., Kehoe, J. M., Williams, R. C., Jr., Feizi, T., and Kunkel, H. G., 1972, Light chain sequences of human IgM cold agglutinins, Proc. Natl. Acad. Sci. U.S.A. 69: 40–43.PubMedGoogle Scholar
  78. Carbone, P. P., Kellerhouse, I. E., and Gehan, E. A., 1967, Plasmacytic myeloma: A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients, Am. J. Med. 12: 937–948.Google Scholar
  79. Carter, P. M., and Hobbs, J. R., 1971, Clinical significance of 7 S IgM in monoclonal IgM diseases, Br. Med. J. 2: 260.PubMedGoogle Scholar
  80. Castaldi, P. A., and Penny, R., 1970, A macroglobulin with antibody activity against coagulation factor VIII, Blood 35: 370.PubMedGoogle Scholar
  81. Cawley, L. P., and Schenken, J. R., 1970, Monoclonal hypergammaglobulinemia of the yM type in a nine–year–old girl with ataxia–telangiectasia. Am. J. Clin. Pathol. 54: 790.PubMedGoogle Scholar
  82. Cemy, J., McAlack, R. F., Sajid, M. A. and Friedman, H., 1971, Genetic differences in the immunocytic response of mice to separate determinants on one bacterial antigen, Nature (London) New Biol. 230: 247.Google Scholar
  83. Chen, Y., Bhoopalam, N., Yakulis, V., and Heller, P., 1975, Changes in lymphocytes surface immunoglobulins in myeloma and the effect of a RNA-containing plasma factor, Ann. Intern. Med. 83: 625.PubMedGoogle Scholar
  84. Christenson, W. N., and Dacie, J. V., 1957, Serum proteins in acquired hemolytic anemia (auto–antibody type), Br. J. Haematol. 3: 153–163.PubMedGoogle Scholar
  85. atosus) beim Macroglobulinämie Waldenstrom,Proc. Utk Int. Congr. Dermatol. Munich 3:142.Google Scholar
  86. Bohrod, M. G., 1957, Plasmacytosis and cryoglobulinemia in cancer, J. Am. Med. Assoc. 164: 18.PubMedGoogle Scholar
  87. Bohrod, M. G., and Böttcher, E. J., 1963, Multiple myeloma, hemolytic anemia and protein phagocytosis, Arch. Pathol. 76: 700–707.PubMedGoogle Scholar
  88. Bonhomme, J., Seligmann, M., Mihaesco, C., Clauvel, J. P., Danon, F., Brouet, J. C., Bouvry, P., Martine, J., and Clerc, M., 1974, Mu–chain disease in an African patient. Blood 43: 485–492.PubMedGoogle Scholar
  89. gammapathies, multiple myeloma and Waldenstrom’s macroglobulinemia,Clin. Exp. Immunol.3:911.Google Scholar
  90. Danby, F. W., Danby, C. W. D., and Pruzanski, W., 1976, Papular mucinosis with IgG(K) M component, Can. Med. Assoc. J. 114: 920–922.PubMedGoogle Scholar
  91. Danon, F., and Seligmann, M., 1972, Transient human monoclonal immunoglobulins, Scand. J. Immunol. 1: 323.PubMedGoogle Scholar
  92. Danon, F., Michaesco, E., Bouvry, M., Clere, M., and Seligmann, M., 1975, A new case of heavy /x– chain disease, Scand. J. Haematol. 15 (l): 5–9.PubMedGoogle Scholar
  93. Darnley, J. D., 1962, Polyneuropathy in Waldenstrom’s macroglobulinemia: Case report and discussion, Neurology 12: 617–623.PubMedGoogle Scholar
  94. Dawson, A. A., and Ogston, D., 1971, Factors influencing the prognosis in myelomatosis. Postgrad. Med. J. 47: 635–638.PubMedGoogle Scholar
  95. Dawson, A. A., and Ogston, D., 1973, High incidence of myelomatosis in north-east Scotland, Scott. Med. J. 18: 75–77.PubMedGoogle Scholar
  96. Dayan, A. D., and Lewis, P. D., 1966, Demyelinating neuropathy in macrocryoglobulinemia. Neurology 16: 1141–1144.PubMedGoogle Scholar
  97. DelDuca, V., Jr., and Morningstar, W. A., 1967, Multiple myeloma associated with progressive multifocal leukoencephalopathy, J. Am. Med. Assoc. 199: 671–673.Google Scholar
  98. Derghazarian, C., and Whittemore, N. B., 1974, Multiple myeloma superimposed on chronic myelocytic leukemia. Can. Med. Assoc. J. 110: 1047–1050.PubMedGoogle Scholar
  99. DiGuglielmo, R., 1966, Unusual morphologic and humoral conditions in the field of plasmocytoms and M-dysproteinemia, Acta Med. Scand. 179 (Suppl. 445): 206.Google Scholar
  100. Dittmar, K., Kochwa, S., Zucker–Franklin D., Gralnick, H., and Wasserman, L. R., 1968, Coexistence of polycythemia and biclonal gammapathy (gamma GK and gamma AL) with two Bence–Jones proteins (BJK and BJL), Blood 31: 881.Google Scholar
  101. Dolin, S., and Dewar, J. P., 1956, Extramedullary plasmacytoma, Am. J. Pathol. 32: 83–103.PubMedGoogle Scholar
  102. Dollinger, M. R., Golby, R. B., and Karnofky, D. A., 1969, Cancer chemotherapy. Dis. Mon. April, p. 11.Google Scholar
  103. Doumenc, J., Prost, R. J., Samama, M., and Bousser, J., 1966, Anomalie de l’agrégation plaquettaire au cours de la maladie de Waldenstrom (à propos de 3 cas), Nouv. Rev. Fr. Hematol. 6: 734.PubMedGoogle Scholar
  104. Drewinko, B., Brown, B. W., Humphrey, R., and Alexanian, R., 1974, Effect of chemotherapy on the labeling index of myeloma cells. Cancer 34: 526.PubMedGoogle Scholar
  105. Drivsholm, A., 1964, Myelomatosis, Acta Med. Scand. 176: 509.PubMedGoogle Scholar
  106. Drivsholm, A., and Clausen, J., 1964, The relationship between the cytology and the immunoelectrophoretic pattern in 105 cases of myelomatosis. Acta Med. Scand. 175: 609.PubMedGoogle Scholar
  107. Dunn, T. B., 1957, Plasma-cell neoplasms beginning in the ileocecal area in strain C3H mice, J. Nad. Cancer Inst. 19: 371.Google Scholar
  108. Dune, B. G., and Salmon, S. E., 1976, A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36: 842–854.Google Scholar
  109. Dutcher, T. F., and Fahey, J. L., 1959, The histopathology of the macroglobulinemia of Waldenstrom, J. Natl. Cancer Inst. 22: 887–917.PubMedGoogle Scholar
  110. Eanes, E. D., and Glenner, G. G., 1968, X-ray diffraction studies on amyloid filaments, J. Histochem. Cytochem. 16: 673.PubMedGoogle Scholar
  111. Ein, D., Kimura, S., and Glenner, G. G., 1972a, An amyloid fibril protein of unknown origin: Partial amino acid sequence analysis, Biochem. Biophys. Res. Commun. 46: 498.PubMedGoogle Scholar
  112. Ein, D., Kimura, S., Terry, W. D., Magnotta, J., and Glenner, G. G., 1972b, Amino acid sequence of an amyloid fibril protein of unknown origin, J. Biol. Chem. 247: 5653.PubMedGoogle Scholar
  113. Eipe, J., Yakulis, V., and Costea, N., 1975, Idiotypic specificity of lymphocyte surface Ig (S Ig) and serum monoclonal IgM in patients with malignant lymphoproliferative disorders, Abstract 107, American Society of Hematology (Eighteenth Annual Meeting), Dallas, Texas.Google Scholar
  114. Elias, E. G., Reynoso, G., and Mittlemann, A., 1972, Control of hypercalcemia with mithramycin, Ann. Surg. 175: 431–435.Google Scholar
  115. Engle, R. I., Jr., and Wallis, I. A., 1957, Multiple myeloma and the adult Fanconi syndrome. 1. Report of a case with crystal-like deposits in the tumor cells and in the epithelial cells of the kidney. Am. J. Med. 22: 5–12.PubMedGoogle Scholar
  116. Engle, R. L., Jr., and Wallis, L. A., 1969, Immunoglobulinopathies, Charles C. Thomas, Springfield, Illinois.Google Scholar
  117. Epstein, F. H., 1968, Calcium and the kidney, Am. J. Med. 45: 700.PubMedGoogle Scholar
  118. Epstein, W. L., 1974, Connective tissue diseases, in: Year Book of Dermatology ( F. D. Malkinson and R. W. Pearson, eds.), p. 271, Year Book Medical Publishers, Chicago.Google Scholar
  119. Essig, L. J., Timms, E. S., Hancock, D. E., and Sharp, G. C., 1974, Plasma cell interstitial pneumonia and macroglobulinemia: A response to corticosteroid and cyclophosphamide therapy, Am. J. Med. 56: 398.PubMedGoogle Scholar
  120. Fadem, R. S., 1952, Differentiation of plasmacytic responses from myelomatous diseases on the basis of bone marrow findings, Cancer 5: 128–137.PubMedGoogle Scholar
  121. Faguet, G. B., Barton, B. P., Smith, L. L. and Garver, F. A., 1977, Gamma heavy chain disease: Clinical aspects and characterization of a deleted, moncovalently linked yl heavy chain dimer (BAZ), Blood 49: 495–505.PubMedGoogle Scholar
  122. Fahey, J. L., 1963, Serum protein disorders causing clinical symptoms in malignant neoplastic disease, J. Chronic Dis. 16: 703–712.PubMedGoogle Scholar
  123. Fahey, J. L., and Askonas, B. A., 1962, Enzymatically produced sub-units of proteins formed by plasma cells in mice. I. γ-Globulin and γ-myeloma proteins, J. Exp. Med. 115: 623.PubMedGoogle Scholar
  124. Fahey, J. L., Scoggins, R., Utz, J. P., and Szwed, C. F., 1963, Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia, Am. J. Med. 35: 698–707.PubMedGoogle Scholar
  125. Fahey, J. L., Barth, W. F., and Solomon, A., 1965, Serum hyperviscosity syndrome, J. Am. Med. Assoc. 192: 464–467.Google Scholar
  126. Fahey, J. L., Carbone, P. P., Rowe, D. S., and Bachmann, R., 1968, Plasma cell myeloma with D-myeloma protein (IgD myeloma). Am. J. Med. 45: 373–380.PubMedGoogle Scholar
  127. Fair, D. S., Krueger, R. G., Gleich, G. J. and Kyle, R., 1974, Studies on IgA and IgG monoclonal proteins derived from a single patient. 1. Evidence for shared individually specific antigenic determinants, J. Immunol. 1974: 112–201.Google Scholar
  128. Fairley, K. F., Barrie, J. U., and Johnson, W., 1972, Sterility and testicular atrophy related to cyclophosphamide therapy, Lancet 1: 568–569.PubMedGoogle Scholar
  129. Farhangi, M., and Osserman, E. F., 1970, Monocytic and monomyelocytic leukemia with lysozymuria as a late complication in plasma cell leukemia, in: Proceedings of the 13th International Congress on Hematology, p. 192, J. F. Lehmanns Verlag, Munich.Google Scholar
  130. Farhangi, M., and Osserman, E. F., 1973, The treatment of multiple myeloma, Semin. Hematol. 10: 149–161.PubMedGoogle Scholar
  131. Farhangi, M., and Osserman, E. F., 1976, Myeloma with xanthoderma due to an IgG λ monoclonal anti-flavin antibody, N. Engl. J. Med. 294: 177.PubMedGoogle Scholar
  132. Farhangi, M., Bukstein, D., Lay, D. E., and Morris, A. D., 1977, Hyperviscosity syndrome and purpura associated with a transient IgA(κ) monoclonal anti-Ig G in a patient with rheumatoid arthritis, Clin. Res. 25: 52A.Google Scholar
  133. Feizi, T., 1967, Lambda chain in cold agglutinins. Science 156: 1111–1112.PubMedGoogle Scholar
  134. Feizi, T., and Schumacher, M., 1968, Light chain homogeneity of postinfective cold agglutinins, Clin. Exp. Immunol. 3: 923–929.PubMedGoogle Scholar
  135. Feizi, T., Kabat, E. A., Vicari, G., Anderson, B., and Marsh, W. L., 1971a, Immunochemical studies on blood groups. XLVII. The I antigen complex-precursors in the A, B, H, Lea and Leb blood group system—Hemagglutination-inhibition studies, J. Exp. Med. 133: 39.PubMedGoogle Scholar
  136. Feizi, T., Kabat, E. A., Vicari, G., Anderson, B., and Marsh, W. L., 1971b, Immunochemical studies on blood groups. XLIX. The I antigen complex: Specificity differences among anti-I sera revealed by quantitative precipitin studies: Partial structure of the I determinant specific for one anti-I serum, J. Immunol. 106: 1578.PubMedGoogle Scholar
  137. Feizi, T., Kabat, E. A., Vicari, G., Anderson, B., and Marsh, W. L., 1972, Immunochemical studies on blood groups. LIV. Classification of anti-I and anti-i sera into groups based on reactivity patterns with various antigens related to the blood group A, B, H, Lea, Leb and precursor substances, J. Exp. Med. 135: 1247.PubMedGoogle Scholar
  138. Feldman, P., Shapiro, L., Pick, A., and Slatkin, M., 1969, Scleromyxedema: A dramatic response to melphalan, Arch. Dermatol. 99: 51.PubMedGoogle Scholar
  139. Ferriman, D. G., and Anderson, A. B., 1956, Macroglobulinemia of Waldenstrom, Br. Med. J. 2: 402–403.PubMedGoogle Scholar
  140. Fett, J. W., and Deutsch, H. F., 1974, The primary structure of the Mcg λ–chain, Biochemistry 13 (20): 4102–4114.PubMedGoogle Scholar
  141. Fine, J. M., Rivat, C., Lambin, P., and Ropartz, C., 1974, Monoclonal IgD: A comparative study of 60 sera with IgD:“M” component, Biomedicine Express (Paris) 21: 119–125.Google Scholar
  142. Finkel, P. N., Kronenberg, K., Pesce, A. J., Pollak, V. E., and Pirani, C. L., 1973, Adult Fanconi syndrome, amyloidosis and marked κ–light chain proteinuria. Nephron 10: 1–24.PubMedGoogle Scholar
  143. Fishman, S. A., and Ritz, N. D., 1975, Erythroleukemia following melphalan therapy for multiple myeloma, N.Y. State J. Med. 75 (13): 2402–2404.PubMedGoogle Scholar
  144. Fitchen, J. H., 1975, Amyloidosis and granulomatous ileocolitis: Regression after surgical removal of the involved bowel, N. Engl. J. Med. 292: 352–353.PubMedGoogle Scholar
  145. Fleischman, J. B., Braun, D. G., and Krause, R. M., 1968, Streptococcal group-specific antibodies: Occurrence of a restricted population following secondary immunization, Pwc. Natl Acad. Sci. U.S.A. 60: 134.Google Scholar
  146. Forte, F. A., Prelli, F., Yount, W. J., Jerry, L. M., Kochwa, S., Franklin, E. C., and Kunkel, H. G., 1970, Heavy chain disease of theµ (γ M) type: Report of the first case. Blood 36: 137–144.PubMedGoogle Scholar
  147. Fowlkes, R. W., Blaylock, W. K., and Mullinax, F., 1967, Immunologic studies in lichen myxedematosus, Arch. Dermatol. 95: 370.PubMedGoogle Scholar
  148. Frangione, B., and Franklin, E. C., 1973, Heavy chain diseases: Clinical features and molecular significance of the disordered immunoglobulin structure, Semin. Hematol. 10: 53–64.PubMedGoogle Scholar
  149. Franklin, E. C., 1975,µ-Chain disease. Arch. Intern. Med. 135: 71–72.Google Scholar
  150. Franklin, E. C., and Frangione, B., 1975, Structural variants of human and murine immunoglobulins, in: Contemporary Topics in Molecular Immunology, Vol. 4 ( F. P. Inman and W. J. Mandy, eds.), p. 89, Plenum Press. New York.Google Scholar
  151. Franklin, E. C., Lowenstein, J., Bigelow, B., and Meltzer, M., 1964, Heavy chain disease—a new disorder of serum γ–globulins: Report of the first case. Am. J. Med. 37: 332–350.PubMedGoogle Scholar
  152. Franklin, E. C., Rosenthal, C. J., and Pras, M., 1975, Studies on the amyloid A protein (AA protein) and a related serum component: Purification, partial characterization and tissue origin and distribution in different types of amyloidosis. Adv. Nephrol. 5: 89.Google Scholar
  153. Fudenberg, J. K., Epstein, H., Shuster, W. L., and Shuster, J., 1967, Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus), Clin. Exp. Immunol. 2: 153–166.PubMedGoogle Scholar
  154. Furie, B., Green, E., and Furie, B. C., 1977, Syndrome of acquired factor X deficiency and systemic amyloidosis. In vivo studies of the metabolic fate of factor X, N. Engl. J. Med. 297: 81–85.PubMedGoogle Scholar
  155. Gach, J., Simar, I., and Salmon, J., 1971, Multiple myeloma without M-type proteinemia: Report of a case with immunologic and ultrastructure studies. Am. J. Med. 50: 835–844.PubMedGoogle Scholar
  156. Galton, D. A. G., and Peto, R., 1973, Report on first myelomatosis trial. I. Analysis of presenting features of prognostic importance, Br. J. Haematol. 24: 123.Google Scholar
  157. Garver, F. A., Chang, L., Mendicino, J., Isobe, T., and Osserman, E. F., 1975, Primary structure of a deleted human lambda type immunoglobulin light chain containing carbohydrate protein Sm λ, Proc. Natl. Acad. Sci. U.S.A. 72: 4559–4563.PubMedGoogle Scholar
  158. Gerber, M. A., 1970, Asbestosis and neoplastic disorders of the hematopoietic system. Am. J. Clin. Pathol. 53: 204–208.PubMedGoogle Scholar
  159. Getaz, P., Handler, L., and Tunley, P. J. I., 1974, Osteosclerotic myeloma with peripheral neuropathy, Afr. Med. J. 48 (29): 1246–1250.Google Scholar
  160. Ghanta, V. K., and Hiramoto, R. N., 1974, Quantitation of total-body tumor cells (MOPC 104E), 1. Subcutaneous tumor model, J. Natl. Cancer Inst. 52: 1199–1202.PubMedGoogle Scholar
  161. Glenner, G. G., and Page, D. L., 1976, Amyloid, amyloidosis, and amyloidogenesis, Int. Rev. Exp. Pathol. 15: 1–92.PubMedGoogle Scholar
  162. Glenner, G. G., Cuatrecasas, P., Isersky, C., Bladen, H. A., and Eanes, E. D., 1969, Physical and chemical properties of amyloid fibers. II. Isolation of a unique protein constituting the major component from human splenic amyloid fibril concentrates, J. Histohem. Cytochem. 17: 769.Google Scholar
  163. Glenner, G. G., Harbaugh, J., Ohms, J. L., Harada, M., and Cuatrecasas, P., 1970, An amyloid protein: The amino-terminal variable fragment of an immunoglobulin light chain, Biochem. Biophys. Res. Commun. 41: 1287.PubMedGoogle Scholar
  164. Glenner, G. G., Terry, W., Harada, M., Isersky, C., and Page, D., 1971a, Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 172: 1150.PubMedGoogle Scholar
  165. Glenner, G. G., Ein, D., Eanes, E. D., Bladen, H. A., Terry, W., and Page, D., 1971b, The creation of “amyloid” fibrils from Bence Jones proteins in vitro, Science 174: 712.Google Scholar
  166. Glenner, G. G., Harada, M., and Isersky, C., 1972a, The purification of amyloid fibril proteins. Prep. Biochem. 2: 39.PubMedGoogle Scholar
  167. Glenner, G. G., Eanes, E. D., and Page, D. L., 1972b, The relation of Congo red staining of amyloid fibrils to the β-conformation, J. Histochem. Cytochem. 20: 821.PubMedGoogle Scholar
  168. Glenner, G. G., Terry, W. D., and Isersky, C., 1973, Amyloidosis: Its nature and pathogenesis, Semin. Hematol. 10: 65.PubMedGoogle Scholar
  169. Glueck, H. I., and Hong, R., 1965, A circulating anticoagulant in γl-A multiple myeloma: Its modification by penicillin, J. Clin. Invest. 44: 1866.PubMedGoogle Scholar
  170. Golde, D. W., Saxon, A., and Stevens, R. H., 1977, Macroglobulinemia and hairy-cell leukemia, N. Engl. J. Med. 296: 92–93.PubMedGoogle Scholar
  171. Gonzales, F., Trujilio, J. M., and Alexanian, R., 1977, Acute leukemia in multiple myeloma, Ann. Intern. Med. 86: 440–443.Google Scholar
  172. Goodman, S. I., Rodgerson, D. O., and Kauffman, J., 1967, Hypercupremia in a patient with multiple myeloma, J. Lab. Clin. Med. 70: 57–62.PubMedGoogle Scholar
  173. Gordon, H., Bandmann, M., and Sandbank, U., 1971, Multiple myeloma associated with progressive multifocal leukoencephalopathy and Pneumocystis carinii pneumonia, Isr. J. Med. Sci. 7: 581–588.PubMedGoogle Scholar
  174. Graham, R. C., Jr., and Bemier, G. M., 1975, The bone marrow in multiple myeloma: Correlation of plasma cell ultrastmcture and clinical state, Medicine (Baltimore) 54: 225–243.Google Scholar
  175. Grant, J. A., Blumenschein, G. R., and Buckley, C. E., Ill, 1971, Familial paraproteinemia. Arch. Intern. Med. 128: 427.Google Scholar
  176. Grey, H. M., and Kohler, P. F., 1973, Cryoimmunoglobulins, Semin. Hematol. 10: 87–112.PubMedGoogle Scholar
  177. Groch, G. S., Perillie, P. E., and Finch, S. C., 1965, Reticuloendothelial phagocytic ftinction in patients with leukemia, lymphoma and multiple myeloma. Blood 26: 489–499.PubMedGoogle Scholar
  178. Gueft, B., Kikkawa, Y., and Hirschel, S., 1968, An electron-microscopic study of amyloidosis from different species, in: Amyloidosis ( E. Mandema, L. Ruinen, J. H. Schölten, and A. S. Cohen, eds.), pp. 172–183, Excerpta Medica, Amsterdam.Google Scholar
  179. Gunz, F. W., and Veale, A. M. O., 1969, Leukemia in close relatives-accident or predisposition?, J. Natl. Cancer Inst 42: 517.PubMedGoogle Scholar
  180. Gupta, N. M., Datta, B. N., and Talwar, B. L., 1974, Plasmacytoma of stomach-A case report and review of literature, Indian J. Cancer ll(3): 355–359.Google Scholar
  181. Hällen, J., 1966, Discrete gammoglobulin (M-) components in serum, Acta Med. Scand. 179 (Suppl. 462).Google Scholar
  182. Hallen, J., 1969, DifFerentialdiagnostik vid monoclonal gammapati, Nord. Med. 82: 885–890.PubMedGoogle Scholar
  183. Hallen, J., and Rudin, R., 1966, Peri-collagenous amyloidosis, a study of 51 cases. Acta Med. Scand. 179: 483.PubMedGoogle Scholar
  184. Hannestad, K., and Sletten, K., 1971, Multiple M-components in a single individual. III. Heterogeneity of M-components in two macroglobulinemia sera with anti-polysaccharide activity, J. Biol. Chem. 246 (22): 6982–6990.PubMedGoogle Scholar
  185. Hansen, O. P., Jessen, B., and Videback, A., 1973, Prognosis of myelomatosis on treatment with prednisone and cytostatics, Scand. J. Haematol. 10: 282–290.PubMedGoogle Scholar
  186. Harboe, M., and Torsvik, H., 1969, Protein abnormalities in the cold hemagglutination syndrome, Scand. J. Haematol. 6: 416–426.PubMedGoogle Scholar
  187. Harboe, M., Van Furth, R., Schubothe, H., Lind, K., and Evans, R. S., 1965, Exchange occurrence of κ-chains in isolated cold hemagglutinins, Scand. J. Haematol. 2: 259–266.PubMedGoogle Scholar
  188. Harisdaugkul, V., and Srichaikul, T., 1976, A case of IgD myeloma with clinical manifestation resembling malignant lymphoma, J. Med. Assoc. Thailand 59: 331–337.Google Scholar
  189. Harley, J. B., Ramanan, S. V., Kim, I., Thiagarajan, P. V., Chen, J. H., Gomez, R., Koppel, D., Hyde, F., Gustke, S., and Krall, J., 1972, The cyclic use of multiple alkylating agents in multiple myeloma, W. V. Med. J. 68: 1–3.PubMedGoogle Scholar
  190. Harris, J., and Copeland, D., 1974, Impaired immunoresponsiveness in tumor patients, Ann. N. Y. Acad Sci. 230: 56–85.PubMedGoogle Scholar
  191. Harris, J., Alexanian, R., Hersh, E., and Migliore, P., 1971, Immune function in multiple myeloma: Impaired responsiveness to keyhole limpet hemocyanin, Can. Med. Assoc. J. 104: 389–392.PubMedGoogle Scholar
  192. Harrison, C. V., 1972, The morphology of the lymph node in the macroglobulinaemia of Waldenstrom, J. Clin. Pathol. 25: 12–16.PubMedGoogle Scholar
  193. Heilmann, D., 1957, Plasmocytom auf dem Boden einer chronischen Osteomyelitis bei gleichzeitiger Osteitis deformans, Muench. Med. Wochenschr. 99: 1586.Google Scholar
  194. Heinemann, H. O., 1963, Reversible defect in renal ammonia excretion in patients with hypercalcemia, Metabolism 12: 792.PubMedGoogle Scholar
  195. Heller, P., et al, 1973, The role of RNA in the immunological deficiency of plasmacytoma, Ann. N.Y. Acad. Sci. 207: 468–480.PubMedGoogle Scholar
  196. Helyer, B. J., and Howie, J. B., 1963, Spontaneous autoimmune disease in NZB/Bl mice, Br. J. Haematol. 9: 119.PubMedGoogle Scholar
  197. Howell, G. M., and Alexanian, R., 1976, Multiple myeloma in young persons, Ann. Intern. Med. 84:441– 443.Google Scholar
  198. Higby, D. J., andOhnuma, T., 1975, Plasmacytoma cell ascites, N.Y. State J. Med. 75 (7): 1074–1076.PubMedGoogle Scholar
  199. Hijmans, W., 1975, Waldenstrom’s disease with an IgA paraprotein, Acta Med. Scand. 198 (6): 519–523.PubMedGoogle Scholar
  200. Hippe, E., Jensen, K. B., Olesen, H., Lind, K., andThomsen, P. E. B., 1970, Chlorambucil treatment of patients with cold agglutinin syndrome, Blood 35: 68.PubMedGoogle Scholar
  201. Hobbs, J. R., 1967, Paraproteins, benign or malignant?, Br. Med. J. 3: 699–704.PubMedGoogle Scholar
  202. Hobbs, J. R., 1969a, Paraproteinemia, Proc. R. Soc. Med. 62: 773.PubMedGoogle Scholar
  203. Hobbs, J. R., 1969b, Immunochemical classes of myelomatosis: Including data from a therapeutic trial concluded by a Medical Research Council working party, Br. J. Haematol. 16: 599–606.PubMedGoogle Scholar
  204. Hobbs, J. R., 1969c, Growth rate and responses to treatment in human myelomatosis, Br. J. Haematol. 16: 607–617.PubMedGoogle Scholar
  205. Hobbs, J. R., 1971, Immunocytoma o’mice an’man, Br. Med. J. 2: 67–72.PubMedGoogle Scholar
  206. Hobbs, J. R., Slot, G. M. J., Campbell, C. H., Clein, G. P., Scott, J. T., Crowther, D., and Swan, H. T., 1966, Six cases of gamma-D myelomatosis. Lancet 2: 614–618.PubMedGoogle Scholar
  207. Holland, J. F., Hosley, H., Scharlau, C., Carbone, P. P., Frei, E., III, Brindley, C. O., Hall, T. C., Shnider, B. I., Gold, G. L., Lasagna, L., Owens, A. H., Jr., and Miller, S. P., 1966, A control trial of urethane treatment in multiple myeloma, Blood 27: 328.PubMedGoogle Scholar
  208. Hollander, V. P., Takakura, K., and Yamada, H., 1968, Endocrine factors in the pathogenesis of plasma cell tumors, Recent Prog. Horm. Res. 24: 81–137.PubMedGoogle Scholar
  209. Hoogstraten, B., 1973, Steroid therapy of multiple myeloma and macroglobulinemia, Med. Clin. North Am. 57: 1321–1330.PubMedGoogle Scholar
  210. Hoogstraten, B., Sheehe, P. R., Cuttner, J., Cooper, T., Kyle, R. A., Oberfield, R. A., Townsend, S. R., Harley, J. B., Hayes, D. M., Costa, G., and Holland, J. F., 1967, Melphalan in multiple myeloma. Blood 30: 74.PubMedGoogle Scholar
  211. Hoogstraten, B., Costa, J., Cuttner, J., Forcier, J., Leone, L. A., Harley, J. R., and Glidewell, O. J., 1969, Intermittent melphalan therapy in multiple myeloma, J. Am. Med. Assoc. 209: 251.Google Scholar
  212. Hopper, J. E., 1975, Comparative studies on monotypic IgM λ and IgG κ from an individual patient. I. Evidence for shared VH idiotypic determinants, J. Immunol 115: 1101–1107.PubMedGoogle Scholar
  213. Hopper, J. E., Noyes, C., Heinrikson, R., and Kessel, J. W., 1976, Comparative studies on monotypic IgMλ. and IgGκ from an individual patient. II. Amino-terminal sequence analyses, J. Immunol. 116: 743.PubMedGoogle Scholar
  214. Horn, M. F., Knapp, M. S., Page, F. T., and Walker, W. H. C., 1969, Adult Fanconi syndrome and multiple myelomatosis, J. Clin. Pathol. 22: 414–416.PubMedGoogle Scholar
  215. Hossfeld, D. K., Holland, J. F., Cooper, R. G., and Ellison, R. R., 1975, Chromosome studies in acute leukemias developing in patients with multiple myeloma. Cancer Res. 35 (10): 2808–2813.PubMedGoogle Scholar
  216. Howatson, A. F., and McCulloch, E. A., 1958, Viruslike bodies in a transplantable mouse plasma cell tumor. Nature (London) 181: 1213–1214.Google Scholar
  217. Howell, M., 1963, Acquired factor X deficiency associated with systematized amyloidosis: Report of a case, Blood 21: 739–744.PubMedGoogle Scholar
  218. Hurez, D., Preud’homme, J. L., and Seligmann, M., 1970, Intracellular “monoclonal” immunoglobulin in nonsecretory human myeloma, J. Immunol. 101: 263–264.Google Scholar
  219. Huth, K., Ehlers, G., Knoth, W., Kunze, K., Löffler, H., Mähr, G., and Petzoldt, 1972, Lichen myxoedematosus bei Makroglobulinämie Waldenstrom mit Polyneuropathie und Carpal-tunnel-syndrome, Dtsch. Med. Wochenschr. 97: 152.Google Scholar
  220. Indiveri, F., Barabino, A., Santolini, M E., and Santolini, B., 1974, “Nonsecretory” multiple myeloma: Report of a case. Acta Haematol (Basel) 51:302–309.Google Scholar
  221. Isobe, T. and Osserman, E. F., 1971, Pathologie conditions associated with plasma cell dyscrasias: A study of 806 cases, Ann. N.Y. Acad. Sci. 190: 507–518.PubMedGoogle Scholar
  222. Isobe, T., and Osserman, E. F., 1974a, Plasma cell dyscrasia associated wih the production of incomplete (deleted) IgG λ molecules, gamma heavy chains, and free lambda chains containing carbohydrate: Description of the first case. Blood 43: 505–526.PubMedGoogle Scholar
  223. Isobe, T., and Osserman, E. F., 1974b, Patterns of amyloidosis and their association with plasma cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins, N. Engl. J. Med. 290: 473–477.PubMedGoogle Scholar
  224. Isobe, T., and Osserman, E. F., 1976, Effect of dimethyl sulfoxide (DMSO) on Bence-Jones proteins, amyloid fibrils and casein-induced amyloidosis, in: Amyloidosis ( O. Vegelius and A. Pasternack, eds.), p. 247, Academic Press, London.Google Scholar
  225. Isobe, T., Ikeda, Y., Ohta, H., and Sinura, H., 1976, IgD myeloma, a clinical study of 9 cases, Acta Haematol Jpn. 39: 343–344.Google Scholar
  226. James, K., Fudenberg, H., Epstein, W. L., and Shuster, J., 1967, Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus), Clin. Exp. Immunol. 2: 153–166.PubMedGoogle Scholar
  227. Jancelewicz, Z., Takatsuki, K., Sugai, S., and Pruzanski, W., 1975, IgD multiple myeloma: Review of 133 cases, Arch. Intern. Med. 135: 87–93.PubMedGoogle Scholar
  228. Jasin, J. E., Lospalluto, J., and Ziff, M., 1970, Rheumatoid hyperviscosity syndrome, Am. J. Med. 49: 484.PubMedGoogle Scholar
  229. Jensen, K., 1970a, Metabolism of Bence Jones proteins in non–myeloma patients with normal renal function, Scand. J. Clin. Lab. Invest. 25: 281–289.PubMedGoogle Scholar
  230. Jensen, K., 1970b, Metabolism of Bence Jones proteins in multiple myeloma patients and in patients with renal disease, Scand. J. Clin. Lab. Invest. 26: 13–21.PubMedGoogle Scholar
  231. Johnson, W. W., and Meadows, D. C., 1971, Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy, N. Engl. J. Med. 284: 290–294.PubMedGoogle Scholar
  232. Jones, N. P., Hilton, P. J., Tighe, J. R., and Hobbs, J. R., 1972, Treatment of “primary” renal amyloidosis with melphalan. Lancet 2: 616–619.PubMedGoogle Scholar
  233. Jonsson, V., Videbek, A., Axelsen, N. H., and Harhoe, M., 1976,µ-Chain disease in a case of chronic lymphocytic leukemia and malignant histiocytoma. I. Clinical aspects, Scand. J. Haematol 16(3):209–217.Google Scholar
  234. Kaplan, G. A., and Bennett, J., 1968, Solitary myeloma of the lumbar spine successfully treated with radiation: Report of a case. Radiology 91: 1017–1018, 1032.Google Scholar
  235. Kaye, R. L., Martin, W. J., Campbell, D. C., and Lipscomb, P. R., 1961, Long survival in disseminated myeloma with onset as solitary lesion: Two cases, Ann. Intern. Med. 54: 535–544.PubMedGoogle Scholar
  236. Kedar (Keizman), I., Greenwald, M., and Ravid, M., 1977, Treatment of experimental murine amyloidosis with dimethyl sulfoxide, Eur. J. Clin. Invest. 7: 149.Google Scholar
  237. Keller, H., Spengler, G. A., Skvaril, F., Flury, W., Noseda, G., and Riva, G., 1970, Zur Frage der Heavy chain disease: Ein Fall von IgG-heavy-chain-Fragment-und IgM-Typ K-Para-proteinämie mit Plasmazellenleukämie, Schweiz. Med. Wochenschr. 100: 1012–1022.PubMedGoogle Scholar
  238. Khaleeli, M., Keane, W. M., and Lee, G. R., 1973, Sideroblastic anemia in multiple myeloma: A preleukemic change, Blood 41: 17–25.PubMedGoogle Scholar
  239. Kiang, D. T., Sundberg, R. D., Fortuny, I. E., Brunning, R. D., Theologides, A., Goldman, A., and Kennedy, B. J., 1974, Multiple myeloma: Clinical evolution, Minn. Med. 57: 542–548.PubMedGoogle Scholar
  240. Kim, L., Harley, J. B., and Weksler, B., 1972, Multiple myeloma without initial paraproteins. Am. J. Med. Sci. 264: 267–275.PubMedGoogle Scholar
  241. Kint, A., 1961, Les manifestations cutanées de la maladie de Kahler, Arch. Belg. Dermatol Syphiligr. 17: 148.PubMedGoogle Scholar
  242. Kleinholz, E. J., Jr., and Tennebaum, M. J., 1973, Pleural plasmacytoma presenting as pleural effusion, V. Med. Mon. 100: 1035–1040.Google Scholar
  243. Korsan-Bengsten, K., Hjort, P. F., and Ygge, J., 1962, Acquired factor X deficiency in a patient with amyloidosis, Thromb. Diath. Haemorrh. 7: 558–566.Google Scholar
  244. Korst, D. R., Clifford, G. O., Fowler, W. M., Louis, J., Will, J., and Wüson, H. E., 1964, Multiple myeloma. II. Analysis of cyclophosphamide therapy in 165 patients, J. Am. Med. Assoc. 189: 758.Google Scholar
  245. Kotner, L. M., and Wang, C. G., 1972, Plasmacytoma of the upper air and food passages. Cancer 30: 414–418.PubMedGoogle Scholar
  246. Krajny, M., and Pruzanski, W., 1976, Waldenstrom’s macroglobulinemia: Review of 45 cases, Can. Med. Assoc. J. 114 (10): 899–905.PubMedGoogle Scholar
  247. Krauss, S., and Sokal, J. E., 1966, Paraproteinemias in the lymphomas. Am. J. Med. 40: 400–413.Google Scholar
  248. Kretschmer, R. R., Pizzuto, J., González, J., and López, M., 1974, Heavy chain disease, rheumatoid arthritis and cryoglobulinemia, Clin. Immunol Immunopathol 2: 195–215.PubMedGoogle Scholar
  249. Kuff, E. L., Wivel, N. A., and Lueders, K. R., 1968, The extraction of intracistemal A particles from a mouse plasma-cell tumor, Cancer Res. 28: 2137–2148.PubMedGoogle Scholar
  250. Kuff, E. L., Lueders, K. K., Ozer, H. L., and Wivel, N., 1972, Some structural and antigenic properties of intracistemal A particles occurring in mouse tumors, Proc. Natl Acad. Sci. U.S.A. 69: 218.PubMedGoogle Scholar
  251. Kunwar, K. B., and Kumar, S., 1966, Multiple myeloma with myeloma cells in the urine: Case report, Indiani. Med. Sci. 20: 641–643.Google Scholar
  252. Kyle, R. A., 1975, Multiple myeloma: Review of 869 cases. Mayo Clin. Proc. 50: 29–40.PubMedGoogle Scholar
  253. Kyle, R. A., and Bayrd, E. D., 1961, “Primary” systemic amyloidosis and myeloma: Discussion of relationship and review of 81 cases, Arch. Intern. Med. 107:344–353.Google Scholar
  254. Kyle, R. A. and Bayrd E. D. 1975: Amyloidosis: review of 236 cases. Med. (Baltimore) 54: 271–299.Google Scholar
  255. Kyle, R. A., and Bayrd, E. D., 1976, The Monoclonal Gammopathies, Multiple Myeloma and Related Plasmacell Disorders, Charles C. Thomas, Springfield, Illinois.Google Scholar
  256. Kyle, R. A., Nobrega, F. T., and Kurland, L. T., 1969, Multiple myeloma in Olmsted County, Minnesota, 1945–1964, Blood 33: 739–745.PubMedGoogle Scholar
  257. Kyle, R. A., Pierre, R. V., and Bayrd, E. D., 1970, Multiple myeloma and acute yclononocytic leukemia: Report of four cases possibly related to melphalan, N. Engl. J Med. 283: 1121–1125.PubMedGoogle Scholar
  258. Kyle, R. A., Maldonado, J. E., and Bayrd, E. D., 1973, Idiopathic Bence Jones proteinuria: A distinct entity?. Am. J. Med. 55: 222–226.PubMedGoogle Scholar
  259. Kyle, R. A., Maldonado, J. E., and Bayrd, E. D., 1974a, Plasma cell leukemia: Report on 17 cases. Arch. Intern. Med. 133: 813–818.PubMedGoogle Scholar
  260. Kyle, R. A., Pierre, R. V., and Bayrd, E. D., 1974b, Primary amyloidosis and acute leukemia associated with melphalan therapy. Blood 44: 333–337.PubMedGoogle Scholar
  261. Kyle, R. A., Pierre, R. V., and Bayrd, E. D., 1975a, Multiple myeloma and acute leukemia associated with alkylating agents. Arch. Intern. Med. 135: 185–192.PubMedGoogle Scholar
  262. Kyle, R. A., Seligman, B. R., Wallace, H. J., Jr., Silver, R. T., Glidewell, O., and Holland, J. F., 1975b, Multiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208), Cancer Chemother. Rep. 59: 557–562.PubMedGoogle Scholar
  263. Lackner, H., 1973, Hemostatic abnormalities associated withdysproteinemias, Semin. Hematol. 10: 125–133.PubMedGoogle Scholar
  264. Ladefoged, A. J., Nielsen, B., and Pedersen, K., 1970, Akut nyreinsufficiens ved myelomatose, Ugeskr. Laeg. 132: 641–646.PubMedGoogle Scholar
  265. Lai A Fat, R. F. M., Suurmond, D., Ràdi, J., and van Furth, R., 1973, Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein, IgGi of type kappa, Br. J. Dermatol. 88: 107–116.Google Scholar
  266. Laird, A. K., 1964, Dynamics of tumor growth, Br. J. Cancer 18: 490.Google Scholar
  267. Laird, A. K., 1965, Dynamics of tumor growth: Comparison of growth rates and extrapolation of growth curve to one cell, Br. J. Cancer 19: 278.PubMedGoogle Scholar
  268. Lane, S. L., 1952, Plasmacytoma of the mandible, Oral Surg. 5: 134–142.Google Scholar
  269. Larson, D. L., and Tomlinson, L. J., 1952, Quantitative antibody studies on man. 11. Relation of serum proteins to antibody production, J. Lab. Clin. Med. 39: 129.PubMedGoogle Scholar
  270. Laurell, C. B., 1961, Studies on abnormal serum globulins. Acta Med. Scand., Suppl. 367, p. 17.Google Scholar
  271. Law, I. P., Koch, F. J., Cannon, G. B., Herberman, R. B., and Oldham, R. K., 1976, Acute myelomonocytic leukemia associated with paraproteinemia. Cancer 37 (3): 1359–1364.PubMedGoogle Scholar
  272. Lawson, H. A., Stuart, C. A., Paull, A. M., Phillips, A. M., and Phillips, R. W., 1955, Observations on antibody content of blood in patients with multiple myeloma, N. Engl. J. Med. 252: 13.PubMedGoogle Scholar
  273. Leader, R. W., Wagner, B. M., Henson, J. B., and Gorham, J. R., 1963, Structural and histochemical observations of liver and kidney in Aleutian disease of mink, Am. J. Pathol. 43: 33.PubMedGoogle Scholar
  274. Lee, B. J., Sahakian, G., Clarkson, B. D., and Krakoff, I. H., 1974, Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU, Cancer 33: 533–538.PubMedGoogle Scholar
  275. Lessin, L. S., Hallal, J., Burkholder, P., and Cohen, H., 1972, Ultrastructural studies of the role of the reticuloendothelial (RE) cell in clinical resolution of amyloidosis, Clin. Res. 20: 512.Google Scholar
  276. Levi, D. F., Williams, R. C., Jr., and Lindstrom, F. D., 1%8, Immunofluorescent studies on the myeloma kidney with special reference to light chain disease. Am. J. Med. 44: 922–933.Google Scholar
  277. Levin, M., Franklin, E. C., Frangione, B., and Pras, M., 1972, The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils, J. Clin. Invest. 51: 2773–2776.PubMedGoogle Scholar
  278. Levin, M., Pras, M., and Franklin, E. C., 1973, immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component, J. Exp. Med. 138: 373.Google Scholar
  279. Lewis, A. F., Bergsagel, D. E., Bruce-Robertson, A., Schachter, R. K., and Connell, G. E., 1968, An atypical immunoglobulin. Blood 32: 189.PubMedGoogle Scholar
  280. Lewis, E. B., 1963, Leukemia, multiple myeloma, and aplastic anemia in American radiologists, Science 142: 1492–1494.PubMedGoogle Scholar
  281. Lewis, R. A., Falls, H. F., and Troyer, D. O., 1975, Ocular manifestations of hypercupremia associated with multiple myeloma, Arch. Ophthalmol. 93: 1050–1053.PubMedGoogle Scholar
  282. Lewis, R. A., Hultquist, D. E., Baker, B. L., Falls, H. F., Gershowitz, H., and Penner, J. A., 1976, Hypercupremia associated with a monoclonal immunoglobulin, J. Lab. Clin. Med. 88 (3): 375–388.PubMedGoogle Scholar
  283. Lindqvist, K. J., Ragale, A. H., and Osterland, C. K., 1970, Paraproteinemia in a child with leukemia. Blood 35: 213–221.PubMedGoogle Scholar
  284. Lindström, F. D., Hardy, W. R., Eberle, B. J. and Wüliams, R. C., Jr., 1973, Multiple myeloma and benign monoclonal gammopathy: Differentiation by immunofluorescence of lymphocytes, Ann. Intern. Med. 78: 837–844.PubMedGoogle Scholar
  285. Loeper, M., Vignalou, J., and Borreau, T., 1947, Le myclome suite de traumatisme osseux et d’osteomyelite, Prog. Med. (Paris) 75: 51.Google Scholar
  286. Lowbeer, L., 1969a, Occurrence of osteosclerosis in multiple myeloma, Lab. Med. Bull. Pathol., pp. 396–397.Google Scholar
  287. Lowbeer, L., 1969b, Osteosclerosis in multiple myeloma. Am. J. Clin. Pathol. 52: 757.Google Scholar
  288. Loyau, G., Barre, J. P., L’Hirondel, J. L., Laniece, M., and Preud’homme, J. L., 1975, Maladie des chaines lourdes gamma: A propos d’une nouvelle observation, Nouv. Presse Med. 4 (13): 957–959.PubMedGoogle Scholar
  289. Lynch, P. J., and Winkelmann, R. K., 1966, Generalized plane xanthoma and systemic disease. Arch. Dermatol. 93: 639.PubMedGoogle Scholar
  290. Lyons, R. M., Chaplin, H., Tillack, T. W., and Majerus, P. W., 1975, Gamma heavy chain disease: Rapid sustained response to cyclophosphamide and prednisone. Blood 46: 1–19.PubMedGoogle Scholar
  291. MacKenzie, M. R., and Babcock, J., 1975, Studies of the hyperviscosity syndrome. IL Macroglobulinemia, J. Lab. Clin. Med. 85: 227–234.PubMedGoogle Scholar
  292. MacKenzie, M. R., and Fudenberg, H. H., 1972, Macroglobulinemia: An analysis for forty patients, Blood 39: 874–889.PubMedGoogle Scholar
  293. MacKenzie, M. R., Brown, E., and Fudenberg, H. H., 1968, Hypervolemia in the hyperviscosity syndrome of macroglobulinemia, J. Clin. Invest. 47: 64a.Google Scholar
  294. MacKenzie, M. R., Fudenberg, H. H., and O’Reilly, R. A., 1970, The hyperviscosity syndrome. L In IgG myeloma: The role of protein concentration and molecular shape, J. Clin. Invest. 49: 15.PubMedGoogle Scholar
  295. MacMahon, B.. and Clark, D. W., 1956, The incidence of multiple myeloma, J. Chronic Dis. 4: 508.PubMedGoogle Scholar
  296. Maeda, K., Abesamis, C. M., Kuhn, L. M., and Hyun, B. H., 1973, Multiple myeloma in childhood: Report of a case with breast tumors as a presenting manifestation. Am. J. Clin. Pathol. 60: 552–558.PubMedGoogle Scholar
  297. Magnus-Levy, A., 1931, Bence-Jones-Eiweiss und Amyloid, Z. Klin. Med. 116: 510–531.Google Scholar
  298. Magnus-Levy, A., 1933, Multiple myeloma. VII. Euglobulinämie zur Klinik und Pathologie; Amyloidosis, Z. Klin. Med. 126: 62.Google Scholar
  299. Magnus-Levy, A., 1952, Amyloidosis in multiple myeloma: Progress noted in 50 years of personal observation, J. Mt. Sinai Hosp. N.Y. 19: 8.PubMedGoogle Scholar
  300. Maldonado, J. E., and Kyle, R. A., 1974, Familial myeloma: Report of eight families and a study of serum proteins in their relatives. Am. J. Med. 57: 875–884.PubMedGoogle Scholar
  301. Maldonado, J., Bayrd, E. D., and Brown, A. L., 1965, The flaming cell in multiple myeloma: A light and electron microscopy study. Am. J. Clin. Pathol. 44: 605.PubMedGoogle Scholar
  302. Maldonado, J., Kyle, R. A., Brown, A. L., and Bayrd, E. D., 1966, “Intermediate” cell types and mixed cell proliferations in multiple myeloma: Electron microscopic observations. Blood 27:212.Google Scholar
  303. Maldonado, J. E., Velosa, J. A., Kyle, R. A., Wagoner, R. D., Holly, K. E., and Salassa, R. M., 1975, Fanconi syndrome in adults: A manifestation of a latent form of myeloma. Am. J. Med. 58:354– 364.Google Scholar
  304. Mangalik, A., and Veliath, A. J., 1971, Osteosclerotic myeloma and peripheral neuropathy: A case report, Cancer 28: 1040–1045.PubMedGoogle Scholar
  305. Mangalik, A., and Gupta, P. K., 1974, Soft tissue involvement in plasmacytoma and multiple myeloma: A report of seven cases, Indian J. Pathol. Bacteriol. 17 (l): 45–53.PubMedGoogle Scholar
  306. Marks, J., 1953, Antibody formation in myelomatosis, J. Clin. Pathol. 6: 62–63.PubMedGoogle Scholar
  307. Marlen, R. H., 1963, Xanthomatosis and myelomatosis, Proc. R. Soc. Med. 55: 318.Google Scholar
  308. Martelo, O. J., Schultz, D. R., Pardo, V., and Perez-Stable, E., 1975, Immunologically-mediated renal disease in Waldenstrom’s macroglobulinemia. Am. J. Med. 58 (4): 567–575.PubMedGoogle Scholar
  309. Martin, N. H., 1960, Macroglobulinemia: A clinical and pathological study, Q. J. Med. 29: 179.PubMedGoogle Scholar
  310. Mason, T. J., McKay, F. W., Hoover, R., Blot, W. J., and Fraumeni, J. F., Jr., 1976, Atlas of cancer mortality for U.S. Counties: 1950–1%9, Publication No. (NIH) 75–780, Department of Health, Education and Welfare, Washington, D.C.Google Scholar
  311. Mass, R. E., 1962, A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother. Rep. 16: 257.PubMedGoogle Scholar
  312. Massry, S. G., Mueller, E., Silverman, A. G., and Kleeman, C. R., 1968, Inorganic phosphate treatment of hypercalcemia, Arch. Intern. Med. 121: 307–312.PubMedGoogle Scholar
  313. Mathews, J. W., Jr., and Oliver, C. A., 1974, Osteoblastic multiple myeloma. South. Med. J. 67: 318.PubMedGoogle Scholar
  314. Matsuoka, Y., Moore, G. E., Yagi, Y., and Pressman, D., 1967, Production of free light chains of immunoglobulins by a mematopoietic cell line derived from a patient with multiple myeloma, Proc. Soc. Exp. Biol. Med. 125: 1246.PubMedGoogle Scholar
  315. McArthur, J. R., Athens, J. W., Wintrobe, M. M., and Cartwright, G. E., 1970, Melphalan and myeloma: Experience with a low-dose continuous regimen, Ann. Intern. Med. 72: 665.PubMedGoogle Scholar
  316. McCallister, B. D., Bayrd, E. D., Harrison, E. G., Jr., and McGuckin, W. F., 1967, Primary macroglobu-linemia: Review with a report of thirty-one cases and notes on the value of continuous chlorambucil therapy. Am. J. Med. 43: 394–434.Google Scholar
  317. McCarthy, J. T., Osserman, E. F., Lombardo, P. C., and Takatsuki, K., 1964, An abnormal serum globulin in lichen myxedematosus, Arch. Dermatol. 89: 446.PubMedGoogle Scholar
  318. McCuistion, C. H., and Schoch, E. P., Jr., 1956, Autopsy findings in lichen myxedematosus. Arch. Dermatol. 74: 259.Google Scholar
  319. McDougal, J. S., Hardisdangkul, V., and Christian, C. L., 1975, Naturally occurring low molecular weight IgM in patients with rheumatoid arthritis, systemic lupus erythematosus, and macroglobulinemia. II. Structural studies and comparison of some physiochemical properties of reduced and alkylated IgM, and low molecular weight IgM, J. Immunol. 115: 223–229.PubMedGoogle Scholar
  320. McFadzean, R. M., 1975, Orbital plasma cell myeloma, Br. J. Ophthalmol. 59 (3): 164–165.PubMedGoogle Scholar
  321. McGrath, M. A., and Penny, R., 1976, Blood hyperviscosity and clinical manifestations, J. Clin. Invest. 58: 1155–1162.PubMedGoogle Scholar
  322. Mclntire, K. R., and Princler, G. L., 1969, Prolonged adjuvant stimulation in germ free BALB/c mice: Development of plasma cell neoplasia. Immunology 17: 181.Google Scholar
  323. McLauchlan, J., 1973, Solitary myeloma of the clavicle with long survival after total excision: Report of a case, J. Bone Joint Surg. Br. Vol. 55: 357–358.Google Scholar
  324. McPhedran, P., Heath, C. W., Jr., and Garcia, J., 1972, Multiple myeloma incidence in metropolitan Atlanta, Georgia: Racial and seasonal variations. Blood 39: 866.PubMedGoogle Scholar
  325. Medical Research Council, 1971, Myelomatosis: Comparison of melphalan and cyclophosphamide therapy, Br. Med. J. 1: 640.Google Scholar
  326. Medical Research Council, 1973, Working Party for Therapeutic Trials in Leukaemia, Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance, Br. J. Haematol. 21: 123–139.Google Scholar
  327. Mellors, R. C., 1965, Autoimmune disease in NZB/Bl mice. I. Pathology and pathogenesis of a model system of spontaneous glomerulonephritis, J. Exp. Med. 122: 25.PubMedGoogle Scholar
  328. Mellors, R. C., 1966, Autoimmune disease in NZB/Bl mice. II. Autoimmunity and malignant lymphoma. Blood 27: 435.PubMedGoogle Scholar
  329. Mellors, R. C., and Huang, C. Y., 1966, Immunopathology of NZB/Bl mice. V. Virus-like (filterable) agent separable from lymphoma cells and identifiable by electron microscopy, J. Exp. Med. 124: 1031.PubMedGoogle Scholar
  330. Mellors, R. C., and Huang, C. Y., 1967, Immunopathology of NZB/Bl mice. VI. Virus separable from spleen and pathogenic for Swiss mice, J. Exp. Med. 126: 53.PubMedGoogle Scholar
  331. Mellors, R. C., Aoki, T., and Huebner, R. J., 1969, Further implications of murine leukemia-like virus in the disorders of NZB mice, J. Exp. Med. 129: 1045.PubMedGoogle Scholar
  332. Mellstedt, H., Hammarstrom, S., and Holm, G., 1974, Monoclonal lymphocyte population in human plasma cell myeloma, Clin. Exp. Immunol. 17: 371–384.PubMedGoogle Scholar
  333. Mellstedt, H., Pettersson, D., and Holm, G., 1976, Monoclonal B-lymphocytes in peripheral blood of patients with plasma cell myeloma: Relation to activity of the disease, Scand. J. Haematol. 16:112–120.Google Scholar
  334. Menache, D., and Boivin, P., 1962, Deficit acquis en facteur X chez un malade atteint d’amylose primitive: Injection d’une fraction C.S.B., Nouv. Rev. Er. Hematol. 2: 868–887.Google Scholar
  335. Menkes, C. J., Herreman, G., Preud’homme, J. L., Godeau, P., and Delbarre, F., 1972, Myélome à plasmocytes non excrétants (à propos de deux nouvelles observations), Nouv. Presse Med. 1: 309–312.PubMedGoogle Scholar
  336. Meyers, B. R., Hirschman, S. Z., and Axelrod, J. A., 1972, Current patterns of infection in multiple myeloma, Am. J. Med. 52: 87–92.PubMedGoogle Scholar
  337. Michaux, J. L., and Heremans, J. F., 1969, Thirty cases of monoclonal immunoglobulin disorders other than myeloma or macroglobulinemia: A classification of diseases associated with the production of monoclonal-type immunoglobulins, Am. J. Med. 46: 562–579.PubMedGoogle Scholar
  338. Midwest Cooperative Chemotherapy Group, 1964, Multiple myeloma, J. Am. Med. Assoc. 188: 741.Google Scholar
  339. Miescher, P. A., and Farquet, J. J., 1974, Chronic myelomonocytic leukemia in adults, Semin. Hematol. 11: 129–139.PubMedGoogle Scholar
  340. Migliore, P. J., and Alexanian, R., 1968, Monoclonal gammopathy in human neoplasia. Cancer 21: 1127.PubMedGoogle Scholar
  341. Mihaesco, C., Mihaesco, E., Miglierina, R., Lamaziere, J., Roy, J. P., and Seligmann, M., 1976, Physiochemical and immunological properties of a mu chain disease protein, Immunochemistry 13 (l): 39–45.PubMedGoogle Scholar
  342. Missmahl, H. P., and Hartwig, M., 1953, Virchows Arch. Pathol. Anat. Physiol. 324: 480.Google Scholar
  343. Moertel, C. G., 1966, Multiple primary malignant neoplasms, their incidence and significance. Recent Results Cancer Res. 7: 1–108.Google Scholar
  344. Morgan, C., Jr., and Hammack, W. J., 1966, Intravenous urography in multiple myeloma, N. Engl. J. Med. 275: 77–79.PubMedGoogle Scholar
  345. Moss, W. T., and Ackerman, L. V., 1946, Plasma cell leukemia. Blood 1: 396.PubMedGoogle Scholar
  346. Mundy, G. R., Lulien, R. A., Raisz, L. G., Oppenheim, J. J., and Buell, D. N., 1974a, Bone resolving activity in supernatants fiom lymphoid cell lines, N. Engl. J. Med. 290: 867–871.PubMedGoogle Scholar
  347. Mundy, G. R., Raisz, L. G., Cooper, R. A., Schechter, G. P., and Salmon, S. E., 1974b, Evidence for the secretion of an osteoclast stimulating factor in myeloma, N. Engl. J. Med. 291: 1041–1046.PubMedGoogle Scholar
  348. Myers, G. H., Jr., and Witten, D. M., 1971, Acute renal failure after excretory urography in multiple myeloma (editorial), Am. J. Roentgenol. Radium Ther. Nucl. Med. 113: 583–588.PubMedGoogle Scholar
  349. Namba, Y., and Hanaoka, M., 1969, Immunoglobulin synthesis by cultured mouse myeloma cells, J. Immunol. 102: 1486.PubMedGoogle Scholar
  350. Narasimhan, P., Jagathambal, K., Elizalde, A. M., and Rosner, F., 1975, Chronic lymphocytic leukemia and lymphosarcoma associated with multiple myeloma: Report of three cases. Arch. Intern. Med. 135 (5): 729–732.PubMedGoogle Scholar
  351. Nathans, D., Fahey, J. L., and Potter, M., 1958, The formation of myeloma protein by a mouse plasma cell tumor, J. Exp. Med. 108: 121–129.PubMedGoogle Scholar
  352. New England Journal of Medicine 1972, Case records of the Massachusetts General Hospital, Case 29-1972, 287:138–143.Google Scholar
  353. New England Journal of Medicine, 1976, Case records of the Massachusetts General Hospital, Case 18-1976, 294:998–1002.Google Scholar
  354. Nishiyama, H., Anderson, R. E., Ishimaru, T., Ishida, K., Ii, Y., and Okabe, N., 1973, The incidence of malignant lymphoma and multiple myeloma in Hiroshima and Nagasaki atomic bomb survivorsCancer 32: 1301–1309.PubMedGoogle Scholar
  355. Nosonoff, A., Hopper, J. E., and Spring, S. B., 1975, The Antibody Molecule, Academic Press, New York.Google Scholar
  356. Nutter, D. O., and Kramer, N. C., 1965, Macrocryogelglobulinemia: Report of a case, with unusual spontaneous recovery, Am. J. Med. 38: 462.PubMedGoogle Scholar
  357. von Oberdorfer, A., Schnauffer, K., Lange, H.-J., und Neiss, A., 1973, Zur Verteilung von Paraproteinamien nach Geschlecht und Alter der Patienten, Paraprotein-Klassen,-Subklassen und Leichtketten-Typen. Z. Klin. Chem. Klin. Biochem. 11: 51–64.Google Scholar
  358. O’Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. H., and Bonadonna, G., 1973, Phase II evaluation of adriamycin in human neoplasia, Cancer 32: 1–8.PubMedGoogle Scholar
  359. Olesen, H., 1964, Chlorambucil treatment in the cold agglutinin syndrome, Scand. J. Haematol. 1: 116.PubMedGoogle Scholar
  360. Osgood, E. E., 1960, Survival time of patients with plasmacytic myeloma, Cancer Chemother. Rep. 9: 1.PubMedGoogle Scholar
  361. Osserman, E. F., 1958, Natural history of multiple myeloma before radiological evidence of disease. Radiology 71: 157.PubMedGoogle Scholar
  362. Osserman, E. F., 1959, Plasma–cell myeloma. II. Clinical aspects, N. Engl. J. Med. 261:952 and 1006.Google Scholar
  363. Osserman, E. F., 1961, The plasmacytic dyscrasias. Am. J. Med. 31: 671.PubMedGoogle Scholar
  364. Osserman, E. F., 1967, The association between plasmacytic and monocytic discrasias in man: Clinical and biochemical studies, in: Nobel Symposium 3: Gamma Globulins: Structure and Control of Biosynthesis ( J. Killander, ed.), p. 573, Almquist and Wiksell, Stockholm.Google Scholar
  365. Osserman, E. F., 1969, Clinical and biochemical studies of plasmacytic and monocytic dyscrasias and their interrelationships. Trans. Coll. Physicians Philadelphia 36: 134.Google Scholar
  366. Osserman, E. F., 1971, Multiple myeloma and related plasma cell dyscrasias, in: Immunological Diseases, 3rd Ed. ( M. Samter, ed.), pp. 520–547, Little, Brown and Company, Boston.Google Scholar
  367. Osserman, E. F., 1976, Analysis of amyloid-related Bence-Jones proteins (TEW BJκ and MCG BJλ) and the “non-immunoglobulin” amyloid protein (AUO); hypervariable region homologies and their possible significance, in: Amyloidosis ( O. Vegelius and A. Pasternack, eds.), p. 223, Academic Press, London.Google Scholar
  368. Osserman, E. F., and Farhangi, M., 1972, Plasma cell myeloma, in: Hematology ( Williams, Beutler, Erslev, and Rundles, eds.), pp. 956–968, McGraw-Hill, New York.Google Scholar
  369. Osserman, E. F., and Farhangi, M., 1975, Plasma ceU and monocyte (mono-myelocyte) dyscrasias and their specific protein markers-monoclonal immunoglobulins and lysozyme, in: Excerpta Medica Int. Congr. Ser., No. 349, Vol. 1, Cell Biology and Tumor Immunology: Proceedings of the 12th International Cancer Congress, Florence 1974 ( P. Buculossi, U. Verones’, and N. Cascinelli, eds.), pp. 142–148, Excerpta Medica, Amsterdam.Google Scholar
  370. Osserman, E. F., and Lawlor, D. P., 1966, Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia, J. Exp. Med. 124: 921.PubMedGoogle Scholar
  371. Osserman, E. F., and Takatsuki, K., l%3a, Plasma cell myeloma: Gamma globulin synthesis and structure. Medicine (Baltimore) 42: 357.Google Scholar
  372. Osserman, E. F., and Takatsuki, K., 1963b, Role of an abnormal, myeloma-type serum gamma globulin in the pathogenesis of the skin lesions of papular mucinosis (lichen myxedematosus), Clin. Invest. 42: 962.Google Scholar
  373. Osserman, E. F., and Takatsuki, K., 1964, Clinical and immunochemical studies of four cases of heavy (H γ-2) chain disease, Am. J. Med. 37: 351–373.PubMedGoogle Scholar
  374. Osserman, E. F., and Takatsuki, K., 1965, Considerations regarding the pathogenesis of the plasmacytic dyscrasias, Scand. J. Haematol. 4 (Suppl.): 28.Google Scholar
  375. Osserman, E. F., Talal, N., and Takatsuki, K., 1961, Amyloidosis: Tissue proteinosis: Gammaloidosis (editorial), Ann. Intern. Med. 55: 1033.Google Scholar
  376. Osserman, E. F., Takatsuki, K., and Talal, N., 1964, The pathogenesis of “amyloidosis”: Studies on the role of abnormal gammaglobulins and gammaglobulin fragments of the Bence–Jones (L-polypeptide) types in the pathogenesis of “primary” and “secondary” amyloidosis associated with plasma cell myeloma, Semin. Hematol. 1: 3.PubMedGoogle Scholar
  377. Osserman, E. F., Isobe, T., and Farhangi, M., 1976, Effect of dimethyl sulfoxide (DMSO) in the treatment of amyloidosis, in: Amyloidosis ( O. Vegelius and A. Pasternack, eds.), p. 553, Academic Press, London.Google Scholar
  378. Osterland, C. K., Müler, E. J., Karakawa, W. W., and Krause, R. M., 1966, Characteristics of streptococcal group–specific antibody isolated from hyperimmune rabbits, J. Exp. Med. 123: 599.PubMedGoogle Scholar
  379. Otto, S., Puskas, E., Medgyeski, G. A., and Gergely, J., 1972, Diclonal and multiple gammopathies, Haematologia (Budapest) 6: 471–487.Google Scholar
  380. Ottolander, G. J. H. Den, and Perret, L. J., 1965, Verworven hemorragische idathese ten gevolge van geisoleerde factor X-deficientie, Med. Tijdschr. Geneeskd. 109: 852–854.Google Scholar
  381. Ozer, F. L., and Chaplin, H., 1%3, Agglutination of stored erythrocytes by a human serum, characterization of the serum factor and erythocyte changes, J. Clin. Invest. 42: 1735.Google Scholar
  382. Pachter, M. R., Johnson, S. A., Neblett, T. R., and Truant, J. P., 1959a, Bleeding, platelets, and macroglobulinemia, Am. J. Clin. Pathol. 31 461.Google Scholar
  383. Pachter, M. R., Johnson, S. A., and Basinski, D. H., 1959b, The effect of macroglobulins and their dissociation units on release of platelet factor 3, Thromb. Diath. Haemorrh. 3: 501.PubMedGoogle Scholar
  384. Pambor, M., and Höfs, W., 1968, Lichen myxoedematosus mit konsekutivem Skleromyxödem Arndt Gottron bei Paraproteinämie, seroaktiver Toxoplasmose und Myokardhypoxie, Arch. Klin. Exp. Dermatol. 232: 121.Google Scholar
  385. Pankovich, A. M., and Griem, M. L., 1972, Plasma-cell myeloma: A thirty-year follow-up. Radiology 104: 521–522.PubMedGoogle Scholar
  386. Paraf, A., Coste, T., Rautureau, J., and Texier, J., 1970, La régression de I’amylose: Disparition d’une amylose hépatique massive après nephrectomie pour cancer, Presse Med. 78: 547–548.PubMedGoogle Scholar
  387. Parker, A. C., 1973, A case of acute myelomonocytic leukaemia associated with myelomatosis, Scand. J. Haematol. 11: 257–260.PubMedGoogle Scholar
  388. Parr, D. M., Percy, M. E., and Connell, G. E., 1972, A human immunoglobulin G with deletions in both heavy and light polypeptide chains, Immunochemistry 9: 51–63.PubMedGoogle Scholar
  389. Parson, D. F., Darden, E. B., Jr., Lindsley, D. L., Pratt, G. T., and Edwards, M. P., 1960, Electron microscopy of plasma-cell tumors of the mouse. I. MPC-1 and X5563 tumors, J. Biophys. Biochem. Cytol. 9: 353–368.Google Scholar
  390. Pasmantier, M. W., and Azar, H. A., 1969, Extraskeletal spread in multiple plasma cell myeloma: A review of 57 autopsied cases, Cancer 23: 167–174.PubMedGoogle Scholar
  391. Pearse, A. G. E., Ewen, S. W. B., and Polak, J. M., 1972, The genesis apudamyloid in endocrine polypeptide tumors: Histochemical distinction from immunoamyloid, Virchows Arch. Pathol. Anat. B10: 93.Google Scholar
  392. Pechet, L., and Kastrul, J. J., 1964, Amyloidosis associated with factor X (Stuart) deficiency, Ann. Intern. Med. 61: 315–318.PubMedGoogle Scholar
  393. Pedio, G., Grieshaber, E., and Ruttner, J. R., 1968, On plasmacytoma-oncogenesis of mice. II. Differential ultracentrifugate which contains RNA virus-like particles from HIPA tumor, inducing a plasmacytoid neoplasia in BALB/c mice, Pathol. Microbiol. 32: 241.Google Scholar
  394. Pengelly, C. D., Mondai, B. K., and Barua, A. R., 1973, Hemolytic anemia in myelomatosis, Postgrad. Med. J. 49: 279–281.PubMedGoogle Scholar
  395. Penn, G. M., Kunkel, H. G., and Grey, H. M., 1970, Sharing of individual antigenic determinants between a gamma G and a gamma M protein in a myeloma serum, Proc. Soc. Exp. Biol. Med. 135: 660.PubMedGoogle Scholar
  396. Penny, R., Castaldi, P. A., and Whitsed, H. M., 1971, Inflammation and haemostasis in paraproteinaemias, Br. J. Haematol. 20: 35–44.PubMedGoogle Scholar
  397. Perkins, H. A., MacKenzie, M. R., and Fudenberg, H. H., 1970, Hemostatic defects in dysproteinemias, Blood 35: 695.PubMedGoogle Scholar
  398. Perlia, C. P., Gubisch, N. J., Wolter, J., Edelberg, D., Dederick, M. M., and Taylor, S. G., 1970, Mithramycin treatment of hypercalcemia. Cancer 25: 389–394.PubMedGoogle Scholar
  399. Perry, H. O., Montgomery, H., and Stickney, J. M., 1960, Further observations on lichen myxedematosus, Ann. Intern. Med. 53: 955.PubMedGoogle Scholar
  400. Perry, M. C., and Farhangi, M., 1976 (unpublished case).Google Scholar
  401. Petite, J., and Cruchaud, A.. 1969–1970, Qualitative and quantitative abnormalities of immunoglobulins in relatives of patients with idiopathic paraproteinemia: A study of 12 families, Helv. Med. Acta 35: 248.Google Scholar
  402. Pilgrim, H. I., 1965, The relationship of chronic ulceration of the ileocecal junction to the development of reticuloendothelial tumors in C3H mice. Cancer Res 25: 53.PubMedGoogle Scholar
  403. Pirofsky, B., 1969, Autoimmunization and Autoimmune Hemolytic Anemias, pp. 127–131, Williams and Wilkins Co., Baltimore.Google Scholar
  404. Porter, D. D., Dixon, F. J., and Larsen, A. E., 1965, The development of a myeloma-like condition in mink with Aleutian disease, Blood 25: 736.PubMedGoogle Scholar
  405. Potter, M., 1962, Plasma cell neoplasia in a single host: A mosaic of different protein-producing cell types, J. Exp. Med. 115: 339.PubMedGoogle Scholar
  406. Potter, M., 1972, Immunoglobulin-producing tumors and myeloma proteins of mice, Physiol. Res. 52: 631.Google Scholar
  407. Potter, M., 1973a, The developmental history of the neoplastic plasma cell in mice: A brief review of recent developments, Semin. Hematol. 10: 19.PubMedGoogle Scholar
  408. Potter, M., 1973b, Antigen binding M–components in man and mouse, in: Multiple Myeloma and Related Disorders ( H. A. Azar and M. Potter, eds.), pp. 195–246, Harper and Row, New York.Google Scholar
  409. Potter, M., and Boyce, C. R., 1962, Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral-oil adjuvants, Nature (London) 193: 1086.Google Scholar
  410. Potter, M., and Leon, M. A., 1968, Three IgA myeloma immunoglobulins from the BALB/c mouse: Precipitation with pneumococcal C polysaccharide. Science 162: 369.PubMedGoogle Scholar
  411. Potter, M., and MacCardle, R. C., 1964, Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice, J. Natl. Cancer Inst. 33: 497.PubMedGoogle Scholar
  412. Potter, M., and Robertson, C. L., 1960, Development of plasma-cell neoplasms in BALB/c mice after intraperitoneal injection of parañin-oil adjuvant, heat killed Staphylococcus mixtures, J. Natl. Cancer Inst. 25: 847.PubMedGoogle Scholar
  413. Potter, M., Fahey, J. L., and Pilgrim, H. L, 1957, Abnormal serum protein and bone destruction in transmissible mouse plasma-cell neoplasm, Proc. Soc. Exp. Biol. Med. 94: 321.Google Scholar
  414. Poulik, D., Berman, L., and Prasad, A. S., 1969, “Myeloma protein” in a patient with monocytic leukemia. Blood 33:746.Google Scholar
  415. Pratt, P. W., Estren, S., and Kochwa, S., 1968, Immunoglobulin abnormalities in Gaucher’s disease: Report of 16 cases. Blood 31: 633–640.PubMedGoogle Scholar
  416. Preud’homme, J. L., and Seligmann, M., 1972, Immunoglobulins on the surface of lymphoid cells in Waldenstrom’s macroglobulinemia, J. Clin. Invest. 51: 701–705.PubMedGoogle Scholar
  417. Preud’homme, J. L., Buxbaum, J., and Scharff, M. O., 1973, Mutagenesis of mouse myeloma cells with “melphalan,” Nature (London) 245: 320.Google Scholar
  418. Pringle, J. P., Graham, R. C., and Bernier, G. M., 1974, Detection of myeloma cells in the urine sediment. Blood 43: 137–143.PubMedGoogle Scholar
  419. Pruzanski, W., and Katz, A., 1976, Clinical and laboratory findings in primary generalized and multiple-myeloma-related amyloidosis. Can. Med. Assoc. J. 114: 906–909.PubMedGoogle Scholar
  420. Pruzanski, W., Platts, M. E., and Ogryzlo, M. A., 1969, Leukemic form of immunocytic dyscrasia (plasma cell leukemia): A study of ten cases and a review of the Hterature, Am. J. Med. 47: 60–74.PubMedGoogle Scholar
  421. Pruzanski, W., Warren, R. P., Goldie, J. H. and Katz, A., 1973, Malabsorption syndrome with infiltration of the intestinal wall by extracellular monoclonal macroglobulin, Am. J. Med. 54: 811–818.PubMedGoogle Scholar
  422. Pruzanski, W., Underdown, B., Silver, E. H., and Katz, A., 1974, Macroglobulinemia-myeloma double gammopathy: A study of four cases and a review of the literature, Am. J. Med. 57: 259–266.PubMedGoogle Scholar
  423. Putnam, F. W., Whitley, E. J., Jr., Paul, C., and Davidson, J. N., 1973, Amino acid sequence of aBence Jones protein fiom a case of primary amyloidosis. Biochemistry 12: 3763.PubMedGoogle Scholar
  424. Radl, J., Masopust, J., Houstek, J., and Hrodek, O., 1967, Paraproteinaemia and unusual dys-γ-globulinaemia in a case of Wiskott-Aldrich syndrome. Arch. Dis. Child. 42: 608.PubMedGoogle Scholar
  425. Ravid, M., Kedar (Keizman), I., and Sohar, E., 1977, Effect of a single dose of dimethyl sulfoxide on renal amyloidosis. Lancet 1 (8014): 730–731.Google Scholar
  426. Rees, E. D., and Waugh, W. H., 1965, Factors in the renal failure of multiple myeloma, Arch. Intern. Med. 116: 400–405.PubMedGoogle Scholar
  427. Richardson, E. P., Jr., and Johnson, P. C., 1975, Atypical progressive multifocal leukoencephalopathy with plasma-cell infiltrates. Acta Neuropathol. Suppl. 6/247-250: 2784.Google Scholar
  428. Ritzmann, S. E., Loukas, D., Sakai, H., Daniels, J. C., and Levin, W. C., 1975, Idiopathic (asymptomatic) monoclonal gammopathies. Arch. Intern. Med. 135: 95–106.PubMedGoogle Scholar
  429. Rivers, S. L., and Patno, M. E., 1969, Cyclophosphamide vs. melphalan in treatment of plasma cell myeloma, J. Am. Med. Assoc. 207: 1328.Google Scholar
  430. Rochant, H., Tonthat, H., Etrevenant, M. F., Intrator, L., Sylvestre, R., and Dryfus, B., 1972, Lambda cold agglutinin with anti-Al specificity in a patient with a reticulo-sarcoma, Vox Sang. 1: 45.Google Scholar
  431. Rogers, J. S., II., Spahr, J., Judge, D. M., Varano, L. A., and Eyster, M. E., 1977, IgE myeloma with osteoblastic lesions. Blood 49: 295–299.Google Scholar
  432. Roman, W., and Coles, M., 1966, Paraproteins in folic-acid deficiency. Lancet 1: 211–212.Google Scholar
  433. Rondier, J., Simon, F., Cayla, J., Diebold, J., Bontoux, D., and Delbarre, F., 1975, Myeloma and osteocondensation (apropos of 2 cases), Sem. Hop. 51(3): 157–167 (English abstract).Google Scholar
  434. Rosenthal, C. J., Franklin, E. C., Frangione, B., and Greenspan, J., 1976, Isolation and partial characterization of SAA-an amyloid-related protein from human serum, J. Immunol. 116:1415– 1418.Google Scholar
  435. Rosner, F., and Gninwald, H., 1974 (for Acute Leukemia Group B), Multiple myeloma terminating in acute leukemia: Report of 12 cases and review of the literature. Am. J. Med. 57: 927–939.Google Scholar
  436. Rowe, D. S., and Fahey, J. L., 1965, A new class of human immunoglobulins. I. A unique myeloma protein, J. Exp. Med. 121: 171–184.PubMedGoogle Scholar
  437. Ruben, R. J., Distenfeld, A., Berg, P., and Carr, R., 1969, Sudden sequential deafness as the presenting symptom of macroglobulinemia, J. Am. Med. Assoc. 209: 1364.Google Scholar
  438. Rudders, R. A., Yakulis, V., and Heller, P., 1973, Double myeloma: Production of both IgG type lambda and IgA type lambda myeloma proteins by a single plasma cell line. Am. J. Med. 55: 215.PubMedGoogle Scholar
  439. Rundles, R. W., and Coonrad, E. F., 1957, The treatment of multiple myeloma, in: Proceedings of the Third National Cancer Conference, p. 389, J. B. Lippincott, Philadelphia.Google Scholar
  440. Rundles, R. W., Dillon, M. L., and Dillon, E. S., 1950, Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components and Bence Jones proteinuria, J. Clin. Invest. 29: 1243.PubMedGoogle Scholar
  441. Ryder, R. J. W., 1966, Chronic monocytic leukemia, Blut 14: 47.PubMedGoogle Scholar
  442. Rywlin, A. M., Civantos, F., Ortega, R. S., and Ocminguez, C. J., 1975, Bone marrow histology in monoclonal macroglobulinemia. Am. J. Clin. Pathol. 63 (6): 769–778.PubMedGoogle Scholar
  443. Saidi, P., Uhlman, W. E., and Goldberg, I., 1973, Herpes zoster and multiple myeloma, J. Med. Soc. N.J. 70: 836–838.PubMedGoogle Scholar
  444. Salmon, S. E., 1973, Immunoglobulin synthesis and tumor kinetics of multiple myeloma, Semin. Hematol. 10: 135–147.PubMedGoogle Scholar
  445. Salmon, S. E., 1975, Expansion of the growth fraction in multiple myeloma with alkylating agents, Blood 45: 119–129.PubMedGoogle Scholar
  446. Salmon, S. E., 1976, Nitrosoureas in multiple myeloma. Cancer Treatment Rep. 60: 789–794.Google Scholar
  447. Salmon, S. E., and Durie, B. G. M., 1975, Cellular kinetics in multiple myeloma: A new approach to staging and treatment, Arch. Intern. Med. 135: 131–138.PubMedGoogle Scholar
  448. Salmon, S. E., and Fudenberg, H. H., 1969, Abnormal nucleic acid metabolism of lymphocytes in plasma cell myeloma and macroglobulinemia. Blood 33: 300–312.PubMedGoogle Scholar
  449. Salmon, S. E., and Smith, B. A., 1970a, Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma, J. Clin. Invest. 49: 1114–1121.PubMedGoogle Scholar
  450. Sahnon, S. E., and Smith, B. A., 1970b, Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro, J. Immunol. 104: 665.Google Scholar
  451. Salmon, S. E., Samal, B. A., Hayes, D. M., Hosley, H., Miller, S. P., and Schilling, A., 1967, Role of gamma globulin for immunoprophylaxis in multiple myeloma, N. Engl. J. Med. 277: 1336.PubMedGoogle Scholar
  452. Salmon, S. E., Mackey, G., and Fudenberg, H. H., 1969, “Sandwich” solid phase radioimmunoassay for the quantitative determination of human immunoglobulins, J. Immunol 103:129.Google Scholar
  453. Sanders, J. H., Fahey, J. L., Finegold, L., Ein, D., Reisfeld, R., and Berard, C., 1969, Multiple anomalous immunoglobulins, clinical structural and cellular studies in three patients, Am. J. Med. 47: 43.PubMedGoogle Scholar
  454. Schneider, W., and Missmahl, H. P., 1966, Leichen amyloidosis als Beispiel der perikollagenen, primären, hautbeschränkten und vorweigend umschreibenen Amyloidose, Arch. Klin. Exp. Dermatol. 224: 235.PubMedGoogle Scholar
  455. Schobel, B., and Wewalka, F., 1965, Temporäre “kryptogenetische” Paraproteinämie, Schweiz. Med. Wochenschr. 95: 1301–1304.PubMedGoogle Scholar
  456. Schubert, G. F., and Adam, A., 1974, Glomerular nodules and long-spacing collagen in kidneys of patients with multiple myeloma, J. Clin. Pathol. 27: 800–805.PubMedGoogle Scholar
  457. Schubert, G. E., Veigel, J., and Lennert, K., 1972, Structure and function of the kidney in multiple myeloma, Virchows Arch. A 355: 135–157.Google Scholar
  458. Schubothe, H., 1966, The cold hemagglutinin disease, Semin. Hematol. 3: 27.PubMedGoogle Scholar
  459. Seitanichs, B. A., Shulman, G., and Hobbs, J. R., 1970, Low serum cholesterol with IgA-myelomatosis, Clin. Chim. Acta 29: 93.Google Scholar
  460. Seligmann, M., 1975, Immunochemical, clinical and pathological features of a-chain disease. Arch. Intern. Med. 135: 78–82.PubMedGoogle Scholar
  461. Seligmann, M., and Bäsch, A., 1968, The clinical significance of pathological immunoglobulins, plenary session papers, in: Twelfth Congress of the International Society of Hematology ( E. R. Jaffé, ed.), p. 21–31, Gruñe & Stratton, New York.Google Scholar
  462. Seligmann, M., and Brouet, J. C., 1973, Antibody activities of human myeloma globulin, Semin. Hematol. 10: 163.PubMedGoogle Scholar
  463. Seligmann, M., Danon, F., and Clauvel, J. P., 1971, Natural history of monoclonal immunoglobulins (Myeloma Workshop), Br. Med. J. 2: 321.PubMedGoogle Scholar
  464. Seon, B. K., Yagi, Y., and Pressman, D. J., 1973, Comparative chemical study of α-µ chains from a single patient (SC), J. Immunol. 111: 1285.PubMedGoogle Scholar
  465. Shanbrom, E., Miller, S., and Haar, H., 1960, Herpes zoster in hematologic neoplasias: Some unusual manifestations, Ann. Intern. Med. 53: 523–533.PubMedGoogle Scholar
  466. Shaw, M. T., Twele, T. W., and Nondquist, R. E., 1974, Plasma cell leukemia: Detailed studies and response to therapy. Cancer 33: 619–625.PubMedGoogle Scholar
  467. Shustik, C., Bergsagel, D. E., and Pruzanski, W., 1976, k and k light chain disease: Survival rates and clinical manifestations, Blood 48: 41–51.Google Scholar
  468. Simpson–Harren, L., and Lloyd, H. H., 1970, Kinetic parameter and growth curves for experimental tumor systems. Cancer Chemother. Rep. 54: 143–150.Google Scholar
  469. Skvaril, F., Morell, A., and Barandun,S., 1972, The IgG subclass distribution in 659 myeloma sera. Vox Sang. 23: 546.PubMedGoogle Scholar
  470. Sletten, K., Husby, G., and Natvig, J. B., 1976a, The complete amino acid sequence of an amyloid fibril protein AAl of unusual size (64 residues), Biochem. Biophys. Res. Commun. 69: 19–25.PubMedGoogle Scholar
  471. Sletten, K., Westermark, P., and Natvig, J. B., 1976b, Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid, J. Exp. Med. 143: 993–998.PubMedGoogle Scholar
  472. Smetana, K., Gyorkey, F., Gyorkey, P., and Busch, H., 1973, Ultrastructural studies on human myeloma plasmacytes. Cancer Res. 33: 2300–2309.PubMedGoogle Scholar
  473. Smith, E., Kochwa, S., and Wasserman, L. R., 1965, Aggregation of IgG globulin in vivo. I. The hyperviscosity syndrome in multiple myeloma, Am. J. Med. 39: 35.PubMedGoogle Scholar
  474. Smithies, O., Gibson, D., Fanning, E. M., Goodfiiesh, R. M., Gilman, J. G., and Ballantyne, D. L., 1971, Quantitative procedures for use with the Edman-Begg sequenator. Partial sequences of two unusual immunoglobulin light chains, Rzf and Sac, Biochemistry 10: 4912.PubMedGoogle Scholar
  475. Snapper, L, and Kahn, A., 1971, Myelomatosis, Fundamentals and Clinical Features, University Park Press, Baltimore.Google Scholar
  476. Snapper, I., Turner, L. B., and Moscovitz, H. L., 1953, Multiple Myeloma, Grune & Stratton, New York.Google Scholar
  477. Solomon, A., 1976, Bence-Jones proteins and light chains of immunoglobulins, N. Engl. J. Med. 294: 91–98.PubMedGoogle Scholar
  478. Solomon, A., and Fahey, J. L., 1963, Plasmapheresis therapy in macroglobulinemia, Ann. Intern. Med. 58: 789–800.PubMedGoogle Scholar
  479. Solomon, A., and Kunkel, H. G., 1967, A “monoclonal” type low molecular weight protein related to γM-macroglobulins, Am. J. Med. 42: 958–967.PubMedGoogle Scholar
  480. Solomon, A., Waldmann, T. A., Fahey, J. L., and McFarlane, A. S., 1964. Metabolism of Bence Jones proteins, J. Clin. Invest. 43: 103–117.PubMedGoogle Scholar
  481. Solomon, A., McLaughlin, C. L., and Capra, J. D., 1975, Bence proteins and light chains of immunoglobulins. XI A transient Bence Jones-related protein associated with corticosteroid therapy, J. Clin. Invest. 55: 579–585.PubMedGoogle Scholar
  482. Somer, T., 1975, Hyperviscosity syndrome in plasma cell dyscrasias, Adv. Microcirc. 6: 1–55.Google Scholar
  483. Sorenson, G. D., 1961, Electron microscopic observations of viral particles within myeloma cells of man, Exp. Cell Res. 25: 219.PubMedGoogle Scholar
  484. Sorenson, G. D., 1965, Virus-like particles in myeloma cells of man, Proc. Soc. Exp. Biol. Med. 118: 250.PubMedGoogle Scholar
  485. Soria, J., Soria, C., Samama, M., Fine, J. M., and Bousser, J., 1975, Analysis of fibrin abnormality in case of multiple myeloma, Scand. J. Haematol. 15: 207–218.PubMedGoogle Scholar
  486. Spalter, H. F., 1959, Abnormal serum proteins, and retinal vein thrombosis. Arch. Ophthalmol. 62: 868.PubMedGoogle Scholar
  487. Spengler, G. A., Bütler, R., Fischer, C., Ryssel, H. J., Schmid, E., and Siebner, H., 1966–1967, On the question of familial occurrence of paraproteinemia, Helv. Med. Acta 33: 208.Google Scholar
  488. Spiro, D., 1959, The structural basis of proteinuria in man: Electron microscopic studies of renal biopsy specimens from patients with lipid nephrosis, amyloidosis, and subacute and chronic glomerulonephritis, Am. J. Pathol. 35: 47.PubMedGoogle Scholar
  489. Staples, P. J., and Talal, N., 1969, Relative inability to induce tolerance in adult NZB and NZB/NZW F1 mice, J. Exp. Med. 129: 123.PubMedGoogle Scholar
  490. Stein, R. S., Ellman, L., and Bloch, K. J., 1975, The clinical correlates of IgM M-components: An analysis of thirty-four patients, Am. J. Med Sci. 269: 209–216.PubMedGoogle Scholar
  491. Stites, D. P., and Whitehouse, M. J., 1975, Evolution of multiple myeloma with nonsecreted paraptro-teins, Clin. Res. 23: 283A (abstract).Google Scholar
  492. Stone, M. J., and Frenkel, E. P., 1975, The clinical spectrum of light chain myeloma: A study of 35 patients with special reference to the occurrence of amyloidosis. Am. J. Med. 58: 601–619.PubMedGoogle Scholar
  493. Stoop, J. W., Ballieux, R. E., and Weyers, H. A., 1962, Paraproteinemia with secondary immuneglobulin deficiency in an infant. Pediatrics 29: 97.PubMedGoogle Scholar
  494. Stoop, J. W., Zegers, J. M., Van Heiden, C., and Ballieux, R. E., 1968, Monoclonal gammopathy in a child with leukemia. Blood 32: 774.PubMedGoogle Scholar
  495. Sugai, S., 1972, IgA pyroglobulin, hyperviscosity syndrome and coagulation abnormality in a patient with multiple myeloma, Blood 39: 224.PubMedGoogle Scholar
  496. Suki, W. N., Yium, J. J., Von Minden, M., Sailer-Herbert, C., Eknoyan, G. and Martinez-Maldonado, M., 1970, Acute treatment of hypercalcemia with furosemide, N. Engl. J. Med. 283: 836–841.PubMedGoogle Scholar
  497. Sullivan, P. W., and Salmon, S. E., 1972, Kinetics of growth and regression in IgG multiple myeloma, J. Clin. Invest. 51: 1697–1708.PubMedGoogle Scholar
  498. Taddeini, L., and Schräder, W., 1972, Concomitant myelomonocytic leukemia and multiple myeloma, Minn. Med. 55: 446–448.PubMedGoogle Scholar
  499. Talal, N., Hermann, G., de Vaux St. Cyr, C., and Grabar, P., 1964, Immunoelectrophoretic changes in mouse γ-globulin after intraperitoneal injection of Bayol F, J. Immunol. 92: 747.PubMedGoogle Scholar
  500. Tavassoli, M., and Baughan, M., 1973, Virus like particle in human myeloma without paraproteinemia. Arch. Pathol. 96: 347–349.PubMedGoogle Scholar
  501. Terry, W. D., Page, D. L., Kimura, S., Isobe, T., Osserman, E. F., and Glenner, G. G., 1973, Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis, J. Clin. Invest. 52: 1276–1281.PubMedGoogle Scholar
  502. Thalassmos, N. C., and Joplin, G. F., 1970, Failure of corticosteroid therapy to correct the hypercalcemia of malignant disease, Lancet 2: 537–539.Google Scholar
  503. Thijs, L. G., Hijmans, W., Leene, W., Muntinghe, O. G., Pietersz, R. N. I., and Ploem, J. E., 1970, Blast cell leukaemia associated with IgA paraproteinaemia and Bence Jones protein, Br. J. Haematol. 19: 485.PubMedGoogle Scholar
  504. Thompson, D. L., and Frame, B., 1976, Involutional osteopenia: Current concepts, Ann. Intern. Med. 85: 789–803.Google Scholar
  505. Tuddenham, E. G. C., and Bradley, J., 1974, Plasma volume expansion and increased serum viscosity in myeloma and macroglobulinemia, Clin. Exp. Immunol. 16: 169–176.Google Scholar
  506. Turesson, I., 1975. Nuclear size in benign and malignant plasma cell proliferation. Acta Med. Scand. 197: 7–14.PubMedGoogle Scholar
  507. Tursz, T., Flandrin, G., Brouet, J. C., Briere, J., and Seligmann, M., 1974a, Simultaneous occurrence of acute myelobastic leukaemia and multiple myeloma without previous chemotherapy, Br. Med. J. 2: 642–643.PubMedGoogle Scholar
  508. Tursz, T., Flandrin, G., Brouet, J. C., and Seligmann, M., 1974b, Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment: Study of 4 cases, Nouv. Rev. Fr. Hematol. 14: 693–704.PubMedGoogle Scholar
  509. U.S. Cancer Mortality by County: 1950–1969, U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, DHEW Publication No. (NIH) 74–615.Google Scholar
  510. Velez–Garcia, E.. and Maldonado, N., 1971, Long term follow–up and therapy in multiple myeloma. Cancer 27: 44.Google Scholar
  511. Vermess, M., Pearson, K. D., Einstein, A. B., and Fahey, J. L., 1972, Osseous manifestations of Waldenstrom’s macroglobulinemia, Radiology 102: 497–504.PubMedGoogle Scholar
  512. Victor, M., Banker, B. Q., and Adams, R. D., 1958, The neuropathy of multiple myeloma, J. Neurol. Neurosurg. Psychiatry 21: 73–88.PubMedGoogle Scholar
  513. Vigliano, E. M., and Horowitz, H. I., 1965, Bleeding syndrome caused by interaction of IgA myeloma protein and connective tissue, Blood 26: 880.Google Scholar
  514. Vigliano, E. M., and Horowitz, H. I., 1967, Bleeding syndrome in a patient with IgA myeloma: Interaction of protein and connective tissue, Blood 29: 823.PubMedGoogle Scholar
  515. Vodopick, H., Chaskes, S. J., Solomon, A., and Stewart, J. A., 1974, Transient monoclonalgammopathy associated with cytomegalovirus infection, Blood 44: 189–195.PubMedGoogle Scholar
  516. Wahner, H. W., Kyle, R. A., and Beabow, J. W., 1975, Imaging of multiple myeloma with Tc-99m labeled dyphosphonate, J. Nucl. Med. 16: 579 (abstract).Google Scholar
  517. Waldenstrom, H. J., 1928, On the formation and disappearance of amyloid in man, Acta Chir. Scand. 63: 479.Google Scholar
  518. Waldenstrom, J., 1944, Incipient myelomatosis or “essential” hyperglobulinemia with fibrogenopenia: A new syndrome?. Acta Med. Scand. 117: 216–247.Google Scholar
  519. Waldenstrom, J., 1961, Studies on conditions associated with disturbed gamma globulin formation (gammopathies), Harvey Lect. 56: 211.Google Scholar
  520. Waldenstrom, J., 1965, Macroglobulinemia, in: Immunological Diseases ( M. Samter, ed.). Little, Brown and Company, Boston.Google Scholar
  521. Waldenstrom, J.. 1970. Diagnosis and Treatment of Multiple Myeloma, Grune & Stratton, New York.Google Scholar
  522. Waldenstrom, J., 1973, Benign monoclonal gammopathies, in: Multiple Myeloma and Related Disorders (H. A. Azar and M. Potter, Eds.), pp. Harper & Row, New York.Google Scholar
  523. Waldmann, T. A., and Strober, W., 1969, Metabolism of immunoglobulins, Prog. Allergy 13: 1.PubMedGoogle Scholar
  524. Wall, R. L., and Clausen, K. P., 1975, Carcinoma of the urinary bladder in patients receiving cyclophosphamide, N. Engl. J. Med. 293: 271–273.PubMedGoogle Scholar
  525. Walsh, J. C., 1971, The neuropathy of multiple myeloma: An electrophysiological and histological study, Arch Neurol. 25: 404–414.PubMedGoogle Scholar
  526. Wanebo, H. J., and Clarkson, B. D., 1%5, Essential macroglobulinemia: Report of a case including immunofluorescent and electron microscopic studies, Ann. Intern. Med. 62: 1025–1045.Google Scholar
  527. Wang, A. C., Wang, I. Y. P., McCormick, J. N., and Fudenberg, H. H., 1969, The identity of light chains of monoclonal IgG and monoclonal IgM in one patient, Immunochemistry 6: 451.PubMedGoogle Scholar
  528. Wang, A. C., Wilson, S. K., Hopper, J. E.. Fudenberg, H. H., and Nisonoff, A., 1970, Evidence for control of synthesis of the variable regions of the heavy chains of immunoglobulins G and M by the same gene, Proc. Natl. Acad. Sci. USA 66: 337.Google Scholar
  529. Wang, A. C., Fudenberg, H. H., Goldrosen, M. H., and Freedman, M. H., 1972, Chemical studies of heavy chains of two IgG-X myeloma proteins from a single patient, Immunochemistry 9: 473.PubMedGoogle Scholar
  530. Wang, A. C., Gergely, J., and Fudenberg, H. H., 1973, Aminoacid sequences at constant and variable regions of heavy chains of monotypic immunoglobulins G and M of a single patient. Biochemistry 12: 528.PubMedGoogle Scholar
  531. Wame, G. L., Fairley, K. P., Hobbs, J. B., and Martin, P. I. R., 1973, Cyclophosphamide-induced ovarian failure, N. Engl. J. Med. 289: 1159–1162.Google Scholar
  532. Warner, N. L., and Wistar, R., 1968, Immunoglobulins in NZB/Bl mice: I. Serum immunoglobulin levels and immunoglobulin class of erythrocyte antibody, J. Exp. Med. 127: 169.PubMedGoogle Scholar
  533. Webb, H. E., Harrison, E. G., Jr., Masson, J. K., and ReMine, W. H., 1962, Solitary extramedullary myeloma (plasmacytoma) of the upper part of the respiratory tract and oropharynx. Cancer 15: 1142–1155.PubMedGoogle Scholar
  534. Whitsed, H. M., and Penny, R., 1971, IgA–lgG, cryoglobulinemia with vasculitis, Clin. Exp. Immunol. 9: 183.PubMedGoogle Scholar
  535. Wiedermann, B., Krc, C., Soyka, O., and Vykydal, J., 1966, Plasmozytome mitgeneralisieter Osteosklerose, Folia Haematol. (Leipzig) 86: 47–69.Google Scholar
  536. Williams, H. M., Diamond, H. D., Graver, L. P., and Parsons, H., 1959, Neurological Complications of Lymphomas and Leukemias, Charles C. Thomas, Springfield, Illinois.Google Scholar
  537. Williams, R. C., Jr., 1971, Cold agglutinins: Studies of primary structure, serologic activity and antigenic uniqueness, Ann. N.Y. Acad. Sci. 190: 330–341.PubMedGoogle Scholar
  538. Williams, R. C., Brunning, R. D., and Wollheim, P. A., 1966, Light chain disease: An abortive variant of multiple myeloma, Ann. Intern. Med. 65: 471.PubMedGoogle Scholar
  539. Williams, R. C., Jr., Erickson, J. L., Polesky, H. P., and Swaim, W. R., 1967, Studies of monoclonal immunoglobulins (M-components) in various kindreds, Ann. Intern. Med. 67: 309.PubMedGoogle Scholar
  540. Williams, R. C., Jr., Kunkel, H. G., and Capra, J. D., 1968, Antigenic speciiicies related to the cold agglutinin activity of gamma M globulins. Science 161: 379–381.Google Scholar
  541. Williams, R. C., Bailly, R. C., and Howe, R. B., 1969, Studies of “benign” serum M-components, Am. J. Med. Sci. 257: 275.PubMedGoogle Scholar
  542. Williams, W. J., Beutler, E., Erslev, A. J., and Rundles, R. W., 1972, Hematology, McGraw-Hill, New York.Google Scholar
  543. Wilson, D. E., Flowers, C. M., Hershgold, E. J., and Eaton, R. P., 1975, Multiple myeloma, cryoglobulinemia and xanthomatosis: Distinct clinical biochemical syndromes in two patients, Amer. J. Med. 59: 721–729.PubMedGoogle Scholar
  544. Winterbauer, R. H., Riggins, R. C. K., Griesman, P. A., and Bauermeister, D. E., 1974, Pleuropulmonary manifestations of Waldenstrom’s macroglobulinemia. Chest 66: 368–375.PubMedGoogle Scholar
  545. Wintrobe, M. M., Lee, R. G., Buggs, D. R., Bithell, T. C., Athens, J. W., and Poerster, J., 1974, Clinical Hematology, 7th Ed., Lea and Febiger, Philadelphia.Google Scholar
  546. Witwer, M. W., Schmid, P. R., and Tesar, J. T., 1976, Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout, Br. Med. J. 2 (6027): 89.PubMedGoogle Scholar
  547. Wochner, R. D., Strober, W., and Waldmann, T. A., 1967, The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments, J. Exp. Med. 126: 207–221.PubMedGoogle Scholar
  548. Wood, T. A., and Prenkel, E. P., 1967, An unusual case of macroglobulinemia. Arch. Intern. Med. 119: 631–637.PubMedGoogle Scholar
  549. Wright, C. J. E., 1961, Long survival in solitary plasmacytoma of bone, J Bone Joint Surg. Br. Vol. 43: 767–771.Google Scholar
  550. Yagi, Y., and Pressman, D., 1973, Monoclonal IgA and IgM in the serum of a single patient. I. Sharing of individually specific determinants between IgA and IgM, J. Immunol. 110: 335.PubMedGoogle Scholar
  551. Yakulis, V., Bhoopalam, N., Schade, S., and Heller, P., 1972, Surface immunoglobulins of circulating lymphocytes in mouse plasmacytoma. I. Characteristics of lymphocyte surface immunoglobulins. Blood 39: 453–464.PubMedGoogle Scholar
  552. Yamada, H., Washburn, L. T., Takakura, K., and Hollander, V. P., 1969, The correlation between plasma cell tumor development and antibody response in inbred strains of mice, Proc. Soc. Exp. Biol. Med. 131: 947.PubMedGoogle Scholar
  553. Yentis, L., 1956, The so-called solitary plasmocytoma of bone, J. Fac. Radiol. London 8: 132–144.Google Scholar
  554. Yoshimura, Y., Takada, K., Kawai, N., Hasegawa, K., and Ishikawa, T., 1976, Two cases of plasmacytoma in the oral cavity, Int. J. Oral Surg. 5 (2): 82–91.PubMedGoogle Scholar
  555. Young, V. H., 1969, Transient paraproteins, Proc. R. Soc. Med. 62: 778.PubMedGoogle Scholar
  556. Zawadzki, Z. A., and Edwards, G. A., 1970, Dysimmunoglobulinemia associated with hepatobiliary disorders, Am. J. Med. 48: 196.PubMedGoogle Scholar
  557. Zawadzki, Z. A., and Edwards, G. A., 1972, Non-myelomatous monoclonal immunoglobulinemia, in: Progress in Clinical Immunology, Vol. 1 ( R. S. Schwartz, ed.), pp. 105–156, Grune & Stratton, New York.Google Scholar
  558. Zeffren, J. L., and Heinemann, H. O., 1962, Reversible defect in renal concentrating mechanism in patients with hypercalcemia. Am. J. Med. 33: 54.PubMedGoogle Scholar
  559. Zimelman, A. P., 1973, Thrombocytosis in multiple myeloma (letter to the editor), Ann. Intern. Med. 78: 970–971.PubMedGoogle Scholar
  560. Zinneman, H. H., and Hall, W. H., 1954, Recurrent pneumonia in multiple myeloma and some observations on immunologic response, Ann. Intern. Med. 41: 1152.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1978

Authors and Affiliations

  • Mehdi Farhangi
    • 1
  • Elliott F. Osserman
    • 2
  1. 1.Department of MedicineUniversity of Missouri-ColumbiaColumbiaUSA
  2. 2.Department of MedicineCollege of Physicians and Surgeons, Columbia UniversityNew YorkUSA

Personalised recommendations